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Abstract 
The addiction to opioids and alcohol is one of the most significant public health concerns 
worldwide. One of the current approaches to the treatment of substance use disorders is the use 
of pharmacological therapy. In the United States, five pharmacological agents are approved by 
the Food and Drug Administration for the treatment of opioid use disorder and alcohol use 
disorder. The objective of the research carried out for the purpose of this dissertation is to 
determine the efficacy of these five pharmacological agents in the prevention of relapse in 
patients with opioid and/or alcohol dependence. A literature review of current evidence was 
conducted, and the results of several clinical studies are presented. The results of these studies 
support the efficacy of naltrexone, buprenorphine, and methadone in the treatment of opioid use 
disorder and relapse prevention; and naltrexone, acamprosate, and disulfiram in the treatment of 
alcohol use disorder and relapse prevention when compared to placebo or usual treatment. The 
use of medication-assisted therapy, which involves both pharmacological therapy and behavioral 
therapy, is recommended as the optimal treatment for opioid- and alcohol-addicted patients. 
Future research on the effects of opioid misuse on alcohol use disorder treatment outcomes and 
alcohol use on opioid use disorder treatment outcomes, as well as potential therapeutic 
interventions for co-occurring opioid and alcohol use disorders, is needed. 
Keywords: addiction treatment, opioid use disorder, alcohol use disorder, 
pharmacological therapy, medication-assisted therapy 
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Chapter One: Introduction 
Background 
The disease of addiction. Addiction is defined as “a chronic, relapsing disorder 
characterized by compulsive drug seeking, continued use despite harmful consequences, and 
long-lasting changes in the brain” (National Institute on Drug Abuse, 2018a). Directly caused by 
the repetitive misuse of a substance or number of substances, addiction is generally considered 
both “a complex brain disorder and a mental illness” (National Institute on Drug Abuse, 2018a). 
There are three phenomena that characterize addiction: “craving (preoccupation/anticipation), 
binge/intoxication, and withdrawal/negative affect” (Bevilacqua & Goldman, 2009). An 
addiction to or dependence on a certain substance is also known as a substance use disorder, 
characterized by distorted thinking, behavior, and body functions. The abuse of addictive 
substances “induce adaptive changes in gene expression in brain reward regions,” including 
those areas of the brain associated with judgment, decision making, learning, memory, and 
behavior control (Bevilacqua & Goldman, 2009; American Psychiatric Association, 2017). 
Although the disease of addiction is complex, the physiology of drug use and how it may 
lead to addiction can be explained simply: An experience that makes an individual feel 
good – taking a drug, having sex, eating, etc. – activates the brain’s reward system (or reward 
pathway). The neurotransmitter dopamine is released, prompting the brain to focus on the 
experience and leaving the individual with a powerful memory of the pleasure associated with 
the experience. In the context of addiction, consistent drug use results in overstimulation of the 
reward system; the brain in turn decreases the production of dopamine and reduces dopamine 
receptors (Healthline, n.d.). This leads to drug tolerance, which is discussed later in this chapter. 
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The history of addiction treatment. The roots of understanding the concept of addiction 
can be traced as far back as the 1770s, during which Dr. Benjamin Rush, whose writing on the 
subject of alcohol is considered the most influential in early American history, first 
professionally recognized the problem of alcohol consumption in a condemnation of the level of 
drunkenness among Continental Army soldiers. Dr. Rush was the first individual to suggest that 
chronic heavy alcohol consumption was a progressive medical condition. Although his claims 
were initially viewed as absurd, his efforts “laid the groundwork for the medical treatment of 
drunkenness and marked the birth of the American temperance movement,” which was at first 
characterized by encouraging drinkers to “moderate rather than completely stop their drinking” 
and eventually shifted to an emphasis on total abstinence (White, 2014). 
 It was not until the 19th century that the effects of heavy alcohol consumption on the 
liver, stomach, blood, and nerve and muscle tissue of the extremities were discovered and 
subsequently termed alcoholic cirrhosis, alcoholic gastritis, and alcoholic polyneuropathy. 
In 1881, Carl Wernicke first described “a psychosis accompanied by polyneuritis that was the 
result of chronic alcoholism and its accompanying vitamin B deficiency” (White, 2014). Several 
years later, Sergei Korsakoff described “an organic psychosis of advanced alcoholism 
characterized by polyneuropathy, confusion, impairment of recent memory, confabulation, visual 
and auditory hallucinations, and superficial/stereotyped speech” (White, 2014). These conditions 
came to be known as Wernicke’s syndrome and Korsakoff’s psychosis, respectively. The first 
landmark text on alcoholism, written by Dr. Magnus Huss in 1849, stated that the term chronic 
alcoholism “applies to the collective symptoms of a disordered condition of the mental, motor, 
and sensory functions of the nervous system…affecting individuals who have persisted in the 
abuse of alcoholic liquors” (White, 2014). 
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 The first attempts to actually treat addiction were carried out in institutions specializing 
in the treatment of inebriety. In 1870, the American Association for the Cure of Inebriates was 
founded; by 1902, there were over 100 facilities in the United States specializing in the treatment 
of alcoholism and other addictions. Most of these early institutions were either inebriate homes, 
which provided “a minimal level of treatment activity in addition to room and board,” and 
inebriate asylums, which “tended to be large medically directed facilities” (White, 2014). The 
20th century was marked by the development of many types of addiction treatments, including 
various miracle cures, religious conversion, sterilization, natural therapeutics emphasizing the 
“moral nature” of addiction, water cures, drug therapies for alcoholism, convulsive therapies, 
aversion therapy, and narcotic treatment clinics, among others. 
 Today, twelve-step programs are a major aspect of addiction recovery for millions of 
individuals. It was in 1939 that the first group meeting to call itself Alcoholics Anonymous took 
place. Ten years later, Narcotics Anonymous was born, although the program did not experience 
any real level of success until the early 1970s. The addiction treatment paradigm that exists today 
began to take root in the 1960s, when addiction treatment legislation was first created. Another 
major step in addiction treatment occurred in the 1980s and into the 1990s, when the movement 
away from “alcohol-only” and “drug-only” treatment services spread rapidly. Up until that point, 
treatment services for alcoholism and drug abuse, respectively, had been separate, with the 
two fields believing that “their respective clients suffered from different disorders that sprang 
from different etiologies and required substantially different treatment philosophies and 
techniques” (White, 2014). The trend toward integration was reflected in the growing use of 
terms such as “addiction,” “substance abuse,” “chemical dependency,” and “alcohol, tobacco, 
and other drugs.” 
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 Addiction treatment programs began to transition from informal to formal organizational 
structures with accreditation and licensure, and the field of addiction medicine experienced a 
rebirth with the creation of the American Society on Alcoholism, the American Academy of 
Addictionology, the American Society on Alcoholism and Other Drug Dependencies, and the 
American Society of Addiction Medicine. As the addiction field continued to progress, wider 
public perceptions of addiction started to change. Campaigns launched in the mid-1970s, 
including Operation Understanding, which involved over 50 prominent citizens publicly 
proclaiming their recovery from alcoholism in Washington, D.C., sought to decrease the stigma 
associated with addiction. 
In the 1990s and early 2000s, the concept of addiction as a brain disease gained 
momentum as the scientific community presented evidence that “addiction at its most 
fundamental essence is a neurobiological disorder” (White, 2014). In order to explain the 
concept of addiction “hijacking the brain” to the public, the National Institute on Drug Abuse 
made the following statement: 
The initial decision to take drugs is mostly voluntary. However, when drug abuse takes 
over, a person’s ability to exert self-control can become seriously impaired. Brain 
imaging studies from drug-addicted individuals show physical changes in areas of the 
brain that are critical to judgment, decision-making, learning and memory, and behavioral 
control. Scientists believe these changes alter the way the brain works and may help 
explain the compulsive and destructive behaviors of addiction (White, 2014). 
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 Just as the disease of addiction is complex, the treatment of addiction is intricate in its 
own respect. In 2006, the National Institute on Drug Abuse issued a set of 13 evidence-based 
principles of addiction treatment: 
(1) Addiction is a complex but treatable disease that affects brain function and behavior 
(2) No single treatment is appropriate for everyone 
(3) Treatment needs to be readily available 
(4) Effective treatment attends to multiple needs of the individual, not just his or her drug 
abuse 
(5) Remaining in treatment for an adequate period of time is critical 
(6) Behavioral therapies…are the most commonly used forms of drug abuse treatments 
(7) Medications are an important element of treatment for many patients, especially when 
combined with counseling and other behavioral therapies 
(8) An individual’s treatment and services plan must be assessed continually and 
modified as necessary to ensure that it meets his or her changing needs 
(9) Many drug-addicted individuals also have other mental disorders 
(10) Medically assisted detoxification is only the first stage of addiction treatment and 
by itself does little to change long-term drug abuse 
(11) Treatment does not need to be voluntary to be effective 
(12) Drug use during treatment must be monitored continuously, as lapses during 
treatment do occur 
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(13) Treatment programs should test patients for the presence of HIV/AIDS, 
hepatitis B and C, tuberculosis, and other infectious diseases as well as provide 
targeted risk-reduction counseling, linking patients to treatment if necessary (White, 
2014) 
Although the term “addiction” can be used to describe an unhealthy dependence on a 
number of substances and physical acts (e.g., gambling, sex, food, etc.), two of the most common 
misused and abused substances – opioids and alcohol – will be the focus of this paper. 
Opioid dependence. Opioids are a class of drugs found naturally in the opium poppy plant that 
act in the nervous system “to produce feelings of pleasure and pain relief” (Johns Hopkins 
Medicine, n.d.; National Institutes of Health, Genetics Home Reference, 2019b). Opioids can be 
classified by their effect at opioid receptors in the body: agonists “interact with a receptor to 
produce a maximal response from that receptor,” antagonists “bind to receptors but produce no 
functional response while…preventing an agonist from binding to that receptor,” and partial 
agonists “bind to receptors but elicit only a partial functional response” (Pathan & Williams, 
2012). The receptors at which opioids produce their effects include mu, delta, and kappa (Pathan 
& Williams, 2012). Some opioids, including oxycodone, fentanyl, buprenorphine, methadone, 
oxymorphone, hydrocodone, codeine, and morphine, are legally prescribed to patients by health 
care providers to manage pain, while others, such as heroin, are illegal. Even when prescribed 
and taken appropriately, there is a high risk of addiction in some individuals. Opioid addiction is 
characterized by “a powerful, compulsive urge to use opioid drugs, even when they are no longer 
required medically” (National Institutes of Health, Genetics Home Reference, 2019b). 
 Positive reinforcement plays a major role in opioid addiction and can be described as “a 
central nervous system process that increases the future probability of a behavioral response that 
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has produced a beneficial outcome” (Fields & Margolis, 2015). It has been shown that opioids 
“directly influence circuits that contribute to several different elements of positive 
reinforcement” (Fields & Margolis, 2015). There are many elements that play a role in an 
individual’s risk of developing an opioid addiction, including genetics, environmental factors, 
and the pharmacological effects of the drug(s). Human studies in families and twins have 
identified an “increased genetic risk for addiction in the first-degree relatives of addicts” and 
found that the genetic risk specific to opioid addiction is second only to that for alcohol addiction 
(Bart, 2012). 
Environmental factors that may influence an individual’s risk of developing an opioid 
addiction include the availability of the drugs, the perceived risk of opioid use, certain 
psychosocial stressors, and the individual’s learned coping strategies. The euphoria and abuse 
liability associated with opioids is related to its pharmacological properties, as the “rapidity with 
which a drug enters and then exits the brain is positively correlated with its rewarding and 
reinforcing effects” (Bart, 2012). 
As mentioned earlier, addiction is characterized by three phases: binge/intoxication, 
withdrawal/negative affect, and preoccupation/anticipation, each associated with different 
behavioral and neurobiological mechanisms. The first phase is associated with “positive 
reinforcement and stimulation of the reward system, in which dopamine plays a major role 
during the initial use of drugs and, as drug use becomes more habitual, with stimulation of dorsal 
striatal regions” (Solinas, Belujon, Fernagut, Jaber, & Thiriet, 2019). The second phase, 
withdrawal, is marked by “hypoactivity of the dopamine system and hyperactivation of the stress 
system, which drives negative reinforcement (drugs are taken not for their positive effects but to 
avoid negative emotional states)” (Solinas et al., 2019). The last phase, characterized by drug 
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craving, is associated with “activation of cortical areas and the release of dopamine in areas 
associated with emotions and memory” (Solinas et al., 2019). 
Although they have different mechanisms of action, all drugs increase the extracellular 
levels of dopamine in the striatum, which is “a subcortical structure in the forebrain that forms 
the major input to the basal ganglia” and regulates responses to both rewarding and aversive 
stimuli (Nature, n.d.). While dopamine elevations occur in the early stages of addiction, the 
“repeated, excessive intake of drugs” is instead associated with “a sort of dopamine depletion” 
(Solinas et al., 2019). It has been shown that drug-induced releases of dopamine in addicted 
individuals are “blunted” when compared to drug-naïve controls, suggesting that a tolerance to 
the drug’s reinforcing effects, rather than a sensitization, develops with consistent drug abuse 
(Solinas et al., 2019). 
 The long-term use of opioids causes physical dependence; when those who are dependent 
cease using opioids, they will experience physical and psychological symptoms of withdrawal. 
Although dependence will occur in any individual who uses opioids for an extended period of 
time, “only a small percentage also experience the compulsive, continuing need for the drug that 
characterizes addiction” (National Institutes of Health, Genetics Home Reference, 2019b). Those 
who become addicted often prioritize obtaining and using these drugs over any other activities in 
their lives, negatively impacting both their personal and professional lives and often leading to 
the deterioration of their personal relationships. The prolonged use of opioids leads to physical 
tolerance to the drug, necessitating increasingly higher doses in order to achieve the desired 
effect. This increases the risk of opioid overdose, which occurs when “high doses of opioids 
cause breathing to slow or stop, leading to unconsciousness and death if the overdose is not 
treated immediately” (National Institutes of Health, Genetics Home Reference, 2019b). 
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Alcohol dependence. Short-term alcohol consumption “depresses brain function by 
altering the balance between inhibitory and excitatory neurotransmission” (Valenzuela, 1997). 
While a definitive explanation has yet to be established, a common theory is that the reinforcing 
properties of alcohol “are not produced by the ethanol molecule itself but are dependent upon the 
action of ethanol metabolites/products” (Deehan, Brodie, & Rodd, 2013). A number of 
neurotransmitter systems have been associated with the reinforcing effects of alcohol, including 
dopamine, endogenous opiates, gamma-aminobutyric acid, serotonin, and glutamate acting at the 
N-methyl-D-aspartate receptor (Valenzuela, 1997). 
 The most common pathway by which alcohol (ethanol) is metabolized in the body 
involves two enzymes: alcohol dehydrogenase and aldehyde dehydrogenase. Alcohol 
dehydrogenase metabolizes alcohol to acetaldehyde, “a highly toxic substance and known 
carcinogen” (National Institute on Alcohol Abuse and Alcoholism, 2007). Studies have shown an 
association between acetaldehyde metabolism and a risk for developing alcoholism. Genetic 
polymorphisms in alcohol dehydrogenase and aldehyde dehydrogenase are thought to have a 
protective effect, reducing the likelihood of the development of alcoholism. Evidence suggests 
that this protective effect “may occur through two mechanisms: an increase in the aversive 
effects of ethanol through increased acetaldehyde levels in the periphery and a decrease in 
ethanol reward through a functional alteration in dopamine metabolism” (Deehan, Brodie, & 
Rodd, 2013). There is abundant evidence suggesting that alcoholism is “a complex genetic 
disease,” although there is no one single “gene for alcoholism” (Edenberg & Foroud, 2013). 
Two genes, ADH1B and ALDH2, have been found to have the strongest known effects on the 
risk of developing alcoholism (Edenberg & Foroud, 2013). 
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Chronic alcohol abuse has a significant impact on glutathione, a “principal cellular 
scavenger of free radicals,” which can help fight off pathogens, that plays an important role in a 
number of cellular processes, including cell differentiation, proliferation, and apoptosis 
(Loguercio et al., 1996; Healthline, 2017; Traverso et al., 2013). The concentrations of 
glutathione in the body are “considered to be markers of defensive capability against oxidative 
stress,” which occurs when there is an imbalance between free radical activity and antioxidant 
activity in the body (Loguercio et al., 1996; Healthline, 2017). The free radical damage 
associated with oxidative stress can lead to the development of a number of diseases, including 
diabetes, atherosclerosis, inflammatory conditions, high blood pressure, heart disease, 
neurodegenerative diseases, and cancer (Healthline, 2017). In both humans and animals, alcohol 
“induces a significant decrease of glutathione in the liver and in blood,” which may in turn 
induce cellular damage by free radicals. 
 Alcohol addiction, otherwise known as alcoholism, is a chronic condition characterized 
by “a powerful, compulsive urge to drink alcohol and the inability to stop drinking after starting” 
(National Institutes of Health, Genetics Home Reference, 2019a). The long-term, excessive use 
of alcohol leads to physical tolerance, necessitating increasingly greater amounts in order to 
achieve the desired effect. In those who are alcohol-dependent, the cessation of drinking causes 
physical and psychological symptoms of withdrawal. Alcohol withdrawal is potentially fatal 
without medical intervention. 
 Just as those addicted to opioids will often prioritize obtaining and using drugs over other 
activities in their lives, individuals with alcohol addiction will do the same, at the expense of 
their personal and professional lives and personal relationships. Chronic excessive alcohol use 
may lead to irreversible liver disease, brain dysfunction, nerve damage, stroke, and the 
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development of certain cancers. Excessive drinking may also lead to a potentially 
life-threatening overdose known as alcohol poisoning (National Institutes of Health, Genetics 
Home Reference, 2019a). According to the World Health Organization, the harmful use of 
alcohol “is a component cause of more than 200 disease and injury conditions in individuals, 
most notably alcohol dependence, liver cirrhosis, cancers, and injuries” (n.d.). As mentioned 
earlier, Wernicke’s syndrome and Korsakoff’s psychosis (also known as Wernicke’s 
encephalopathy and Korsakoff’s syndrome and known together as Wernicke-Korsakoff 
syndrome) are conditions caused by a vitamin B1 (thiamine) deficiency common in individuals 
with alcohol use disorder (MedlinePlus, 2018a). 
Relapse. Although many individuals are able to overcome their addictions to the extent 
that they are able to stop using the particular substance or substances for a period of time, relapse 
is not only a potential but a very likely threat. Relapse is defined as “returning to the use of an 
addictive substance or behavior” (National Cancer Institute, n.d.). Relapse to drug and/or alcohol 
use is a gradual process that can be best understood as occurring in three stages: emotional, 
mental, and physical (Melemis, 2015). An emotional relapse may be characterized by bottling up 
emotions, isolating, not attending 12-step meetings, attending meetings but not verbally 
“sharing,” focusing too much on others, and poor eating and/or sleeping habits (Melemis, 2015). 
A mental relapse may be characterized by drug and/or alcohol craving; thinking about people, 
places, and things associated with prior drug/alcohol use; minimizing the consequences of prior 
use or glamorizing prior use; bargaining; lying; looking for relapse opportunities; and planning a 
relapse (Melemis, 2015). Finally, a physical relapse is characterized by the actual using of drugs 
and/or alcohol. 
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 Addiction, whether drug- or alcohol-related, is often characterized by periods of 
abstinence from the substance or substances, followed by a relapse. Indeed, the threat of relapse 
is “one of the most pervasive challenges in the treatment of patients with chemical dependence” 
(Tkacz, Severt, Cacciola, & Ruetsch, 2011). There are a number of factors that may increase the 
probability of relapse in an individual with opioid or alcohol dependence, including “stress, 
renewed contact with the drug, environmental stimuli that signal the availability of the drug, 
family history of substance abuse, and a higher number of undesirable life events” (Tkacz et al., 
2011). Additionally, certain physiological factors that are a consequence of the substance abuse 
itself may affect the probability of relapse; for example, “enduring physical changes in brain 
structure and/or function and modified neurotransmitter levels” (Tkacz et al., 2011). Because 
relapse represents a significant challenge in addiction treatment, identifying potential therapeutic 
modalities that may aid in relapse prevention is of high importance. 
Socio-Economic Impact 
 Although the addicted individual may bear the brunt of its most devastating 
consequences, drug and alcohol addiction has far-reaching implications that negatively affect the 
country’s public health, economy, and society as a whole. In 2016 in the United States, drug 
overdoses resulted in the deaths of over 63,000 individuals, 42,000 of which were opioid 
overdoses (National Institute on Drug Abuse, 2018a; United States Department of Health and 
Human Services, 2019). Excessive alcohol use resulted in the deaths of approximately 88,000 
(National Institute on Drug Abuse, 2018a). Of those approximately 88,000 deaths: 38,584 were 
due to chronic causes, including 14,695 attributed to alcoholic liver disease, 7,847 attributed to 
liver cirrhosis, 3,728 attributed to alcohol dependence syndrome, and 2,022 attributed to alcohol 
abuse; and 49,544 were due to acute causes, including 12,460 caused by motor-vehicle traffic 
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crashes, 8,404 caused by alcohol-related nonalcoholic poisoning, 8,179 caused by alcohol-related 
suicide, and 7,756 caused by alcohol-related homicide (Centers for Disease Control and 
Prevention, 2013). It is estimated that the use of and addiction to drugs, alcohol, and nicotine 
cost the United States over $740 billion per year related to health care, crime, and lost 
productivity (National Institute on Drug Abuse, 2018a). 
 The country is currently in the grips of a major opioid epidemic, with more than 
130 individuals dying of an opioid overdose every day (National Institute on Drug Abuse, 2019). 
The Centers for Disease Control and Prevention estimates that, in the United States, the total 
economic burden of prescription opioid misuse alone is $78.5 billion per year, including the 
costs of “health care, lost productivity, addiction treatment, and criminal justice involvement” 
(National Institute on Drug Abuse, 2019). According to the 2018 National Survey on Drug Use 
and Health, an estimated 2 million individuals aged 12 years and older had an opioid use 
disorder, 14.8 million individuals aged 12 years and older had an alcohol use disorder, and 
21.2 million individuals aged 12 years and older were in need of substance use treatment 
(Substance Abuse and Mental Health Services Administration, 2019). 
 It’s critical to understand that underlying substance use disorder is “a key driver of the 
overdose epidemic,” so expanding access to addiction treatment services is “an essential 
component of a comprehensive response” (Volkow, Frieden, Hyde, & Cha, 2014). 
Pharmacological Therapies for Relapse Prevention 
  Addressing the significant burden of opioid and alcohol addiction requires the 
exploration and utilization of any and all effective treatment strategies. There are a number of 
available treatment options, including pharmacological therapies used for maintenance treatment 
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and relapse prevention. Because standard psychosocial therapy alone is often not sufficient in 
treating substance use disorders, pharmacological therapy has become increasingly important. 
Pharmacological therapy for the treatment of opioid and alcohol dependence follows 
four basic approaches, as stated by Gorelick (1993): 
(1) long-term or maintenance substitution treatment with a cross-tolerant medication, 
(2) long-term or maintenance treatment with an antagonist medication, which blocks the 
effects of the addictive drug, (3) treatment with a medication that acts on the brain to 
reduce the reinforcing effect of or craving for the addictive drug, and (4) alteration of 
drug metabolism to make taking the addictive drug aversive rather than rewarding. 
Currently, there are three drugs approved by the United States Food and Drug 
Administration (FDA) for the treatment of opioid dependence: buprenorphine, methadone, and 
naltrexone (U.S. Food and Drug Administration, 2019). There are also three drugs approved by 
the FDA for the treatment of alcohol dependence (alcohol use disorder): acamprosate, disulfiram, 
and naltrexone (Winslow & Onysko, 2016). 
Naltrexone. Naltrexone (brand names Vivitrol, Revia) blocks the effects of opiates in the 
body by competing with them for opioid receptors in the brain. Regarding alcohol dependence, 
naltrexone has been shown to reduce patients’ urge to drink, help patients remain abstinent from 
drinking, and interfere with patients’ desire to continue drinking after a slip (National Institute on 
Alcohol Abuse and Alcoholism, n.d.). According to the National Institute on Alcohol Abuse and 
Alcoholism (n.d.), side effects of naltrexone treatment include nausea, headache, depression, 
dizziness, fatigue, insomnia, anxiety, and sleepiness. 
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Buprenorphine. Buprenorphine (brand names Subutex, Belbuca, Probuphine, Buprenex, 
Butrans) is a semi-synthetic opioid and partial mu-opioid receptor agonist indicated in opioid 
detoxification and opioid maintenance (Welsh & Valadez-Meltzer, 2005). 
Buprenorphine-naloxone (brand names Suboxone, Zubsolv, Bunavail) “comprises the partial 
mu-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in 
a 4:1 ratio” and works to prevent withdrawal symptoms in opioid-dependent patients by 
producing similar effects (Orman & Keating, 2009; MedlinePlus, 2019). Potential side effects of 
buprenorphine use include headache, stomach pain, constipation, difficulty falling or staying 
asleep, mouth numbness or redness, tongue pain, blurred vision, and back pain (MedlinePlus, 
2019). 
Methadone. Methadone (brand names Diskets, Methadone Intensol, Methadose, 
Dolophine) is a synthetic mu opioid receptor agonist that relieves withdrawal symptoms, “blocks 
the effect of superimposed opiates, … [and] normalizes many of the physiological stress-related 
responses that precede and contribute to relapse” (Bart, 2012). Some common side effects of 
methadone treatment include headache, weight gain, stomach pain, dry mouth, sore tongue, 
flushing, difficulty urinating, mood changes, vision problems, and difficulty falling or staying 
asleep (MedlinePlus, 2018b). 
Acamprosate. Clinical studies suggest that acamprosate (brand name Campral) “lowers 
neuronal excitability by reducing the postsynaptic efficacy of excitatory amino acid 
neurotransmitters” (Sass, Soyka, Mann, & Zieglgänsberger, 1996). It has been shown to 
“attenuate postsynaptic activity of excitatory amino acid agonists in neocortical neurons, 
indicating a potential for modifying the behavioral manifestation that may be associated with 
alcohol intoxication” (Sass et al., 1996). Potential side effects of acamprosate use include 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 25 
diarrhea, gas, upset stomach, loss of appetite, dry mouth, dizziness, itching, weakness, nausea, 
anxiety, difficulty falling or staying asleep, and sweating (MedlinePlus, 2016). 
Disulfiram. Disulfiram (brand name Antabuse) works by irreversibly inhibiting aldehyde 
dehydrogenase by “competing with nicotinamide adenine dinucleotide at the cysteine residue in 
the active site of the enzyme” (Stokes & Abdijadid, 2019). At therapeutic doses, any alcohol 
consumption by the patient results in increased serum acetaldehyde, which in turn causes what is 
known as the disulfiram-alcohol reaction, characterized by symptoms including diaphoresis, 
palpitations, facial flushing, nausea, vertigo, hypotension, and tachycardia; this reaction 
discourages alcohol intake (Stokes & Abdijadid, 2019). The most common of the less serious 
side effects of disulfiram treatment include headache, sleepiness, tiredness, and halitosis 
(metallic taste) (Stokes & Abdijadid, 2019). 
For the purposes of this paper, the aforementioned FDA-approved pharmacological 
agents naltrexone, buprenorphine, methadone, acamprosate, and disulfiram for relapse 
prevention will be the focus of the literature review. 
Research Objective and Questions 
 The objective of this research is to explore certain currently available pharmacological 
therapies and determine their effectiveness in preventing relapse among opioid- and 
alcohol-addicted patients. Identifying these agents and supporting their use in patients with 
opioid and alcohol addiction may improve treatment outcomes and ultimately result in lower 
rates of death, injury, incarceration, and their associated economic costs. The primary research 
question being investigated is: Are currently marketed pharmacological therapies used in opioid 
and alcohol addiction effective in preventing relapse among patients? A secondary research 
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question being investigated is: Is pharmacological therapy in conjunction with a psychosocial 
intervention the optimal treatment strategy in opioid and alcohol use disorders? 
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Chapter Two: Literature Review 
 The use of pharmacological therapies for the treatment of and prevention of relapse in 
opioid and alcohol addiction has been explored in several clinical studies. The objective of this 
literature review is to present the context and results of a number of clinical studies conducted in 
opioid- and alcohol-dependent patients, as well as meta-analyses and systematic reviews of 
various clinical studies, in an effort to determine the efficacy of certain pharmacological 
therapies (specifically, naltrexone, buprenorphine/buprenorphine-naloxone, methadone, 
acamprosate, and disulfiram) in preventing relapse among these patients. 
 The structure of this chapter is based on the therapeutic indication being investigated in 
the study (opioid dependence studies versus alcohol dependence studies) and further classified 
by the specific medication being assessed (for opioid dependence studies: naltrexone, 
buprenorphine/buprenorphine-naloxone, and methadone; for alcohol dependence studies: 
naltrexone, acamprosate, and disulfiram). The results of these studies are further detailed in 
Chapter Four. 
Opioid Dependence Studies 
Naltrexone. A double-blind, placebo-controlled, randomized, multicenter study 
conducted by Krupitsky et al (2011) explored the efficacy, safety, and patient-reported outcomes 
of injectable extended-release naltrexone (XR-NTX) in patients with opioid dependence. 
Two-hundred fifty patients completing inpatient opioid detoxification at 13 clinical sites in 
Russia were randomly assigned to receive an injection of naltrexone or placebo within one week 
after detoxification and every four weeks thereafter, for a total of six injections over the course 
of 24 weeks. Additionally, patients were offered 12 biweekly sessions of individual counseling 
tailored to opioid dependence. 
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 The primary endpoint of this study was the response profile for confirmed opioid 
abstinence during weeks 5 to 24 of the treatment period. Secondary endpoints included 
self-reported opioid-free days according to the timeline follow-back survey, opioid craving 
scores, number of days of retention, and relapse to physiological opioid dependence. To explain 
the importance of measuring both opioid use and physiological dependence, researchers cited the 
fact that the use of opioids might cause relapse to physiological opioid dependence in patients. 
Craving was assessed via a weekly self-report visual analogue scale of the need for opioids 
(scale of 0 to 100; 0=not at all; 100=very much so). 
 After 24 weeks of treatment, the percentage of opioid-free weeks was significantly higher 
in the XR-NTX group than in the placebo group (p=0.0002). The median proportion of patients 
who had confirmed abstinence was higher in the XR-NTX group than in the placebo group 
(p=0.0002). Total abstinence was reported in 36% of patients in the XR-NTX group compared 
with 23% of patients in the placebo group (p=0.0224). All four secondary endpoints showed 
significant differences between the XR-NTX and placebo groups. The median self-report of 
opioid-free days over 24 weeks was 99% for the XR-NTX group compared with 60% for the 
placebo group (p=0.0004). There was “a statistically and clinically significantly greater reduction 
in opioid craving” in the XR-NTX group than in the placebo group by week 8 (p=0.0048), which 
persisted to week 24 of the treatment period (Krupitsky et al., 2011). Relapse to physiological 
opioid dependence occurred in one patient in the XR-NTX group, who had missed two previous 
injections, compared with 17 patients in the placebo group (p<0.0001). 
 In this group of detoxified, opioid-dependent adults, those who received XR-NTX 
experienced more opioid-free weeks than those who received placebo. Treatment with XR-NTX 
demonstrated a persistent anti-craving effect over weeks 8 to 24 of the treatment period. Among 
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patients who received XR-NTX, there was 94% fewer naloxone-confirmed relapses to opioid 
dependence and almost double the median length of retention in treatment compared with those 
who received placebo. The onset of efficacy of XR-NTX was rapid, “with an anti-craving effect 
at week 1, an increase in abstinent days within two weeks, and improved retention at one month” 
(Krupitsky et al., 2011). 
 Although this study had limitations, including a substantial clinical response in patients 
receiving placebo, potential under-reporting of drug use, and population and treatment system 
differences between the geographical setting of the study and the wider population, significant 
differences in favor of treatment with naltrexone were observed. Naltrexone treatment was 
associated with higher rates of opioid-free weeks, total abstinence, and opioid-free days, as well 
as a significant reduction in opioid craving. The findings of this study support the efficacy of 
naltrexone in relapse prevention among opioid-addicted individuals. 
 An open-label, randomized, controlled effectiveness study conducted by Lee et al (2016) 
explored the efficacy of extended-release naltrexone (brand name Vivitrol) in reducing opioid 
relapse compared with “treatment as usual” in opioid-dependent criminal justice system 
offenders. The primary outcome of the study was the time to an opioid relapse during the 
24-week treatment period. Relapse was defined as “10 or more days of opioid use in a 
28-day (four-week) period as assessed by self-report or by testing of urine samples obtained 
every two weeks; a positive or missing sample was computed as five days of opioid use” (Lee et 
al., 2016). Three-hundred and eight patients were randomized to treatment with extended-release 
naltrexone or usual treatment. Patients in the extended-release naltrexone group received 
medication-management counseling; those in the usual treatment group “received similar 
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counseling that was focused on adverse events, the prevention of relapse and overdose, and 
support for community treatment involvement” (Lee et al., 2016). 
 During the 24-week treatment period, the time to relapse was significantly longer among 
patients in the extended-release naltrexone group than in patients in the usual treatment 
group (10.5 weeks versus 5.0 weeks [p<0.001]). A relapse event was detected in 66 patients 
treated with extended-release naltrexone (43%) compared with 99 patients assigned to usual 
treatment (64%) (p<0.001). All recorded fatal or nonfatal overdose events occurred among 
patients assigned to usual treatment, with no events occurring in the extended-release naltrexone 
group and five events from week 0 to 25 and seven events from week 0 to 78 occurring in the 
usual treatment group. After discontinuation, no overdoses occurred among patients in the 
extended-release naltrexone group. 
 Some limitations of this study include that it was not blinded, conducted in only 
one region of the United States, and conducted in individuals who were former or current heroin 
users. Although these may negatively affect generalizability, the fact that the study had an 
open-label effectiveness design may increase its generalizability. Despite the study population 
being limited to individuals who were criminal justice system offenders, the results bode well for 
the wider population of opioid-addicted individuals who may not share the same burdens as 
those with criminal backgrounds (for example, community service commitments, court dates, 
issues with unemployment, etc.). The results of this study indicate that treatment with 
extended-release naltrexone is associated with a lower rate of relapse compared to treatment as 
usual. 
Buprenorphine. A study by Tkacz et al (2011) examined the effects of buprenorphine 
compliance on the rates of relapse in opioid-dependent patients. Seven-hundred and 
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three patients new to buprenorphine completed the Addiction Severity Index at baseline and at 
one, two, and three months post-baseline. Compliance was defined as taking buprenorphine on at 
least 22 of the past 28 days (80%). Patients who reported opioid use at either month 2 or month 3 
were considered “relapsed.” 
 Of the 703 patients, 142 (20%) reported a relapse at either month 2 (63%) or 
month 3 (37%). Analyses showed that patients who were noncompliant to buprenorphine were 
significantly more likely to relapse than those who were compliant to treatment (60.4% versus 
12.7%). In the regression model used by researchers, buprenorphine compliance was a 
significant predictor of relapse, “with buprenorphine noncompliant patients being over 10 times 
more likely to relapse to opioid abuse than buprenorphine compliant patients” (Tkacz et al., 
2011). Results indicate that the patients’ demographic factors and intervention assignment were 
not predictive of relapse. 
 Although the results of this study indicate that buprenorphine is effective in decreasing 
the incidence of relapse among opioid-dependent patients, they also demonstrate that the 
effectiveness of buprenorphine “relies heavily upon patient compliance” (Tkacz et al., 2011). 
There are a number of factors that may influence compliance to buprenorphine and other 
medications, including patients’ comorbid conditions, overall psychological stability, and 
adherence history to other medications. The buprenorphine treatment regimen itself may be a 
factor in noncompliance, as it requires a higher level of self-reliance on the part of the patient 
when compared to other treatments such as methadone, which is administered in a clinic. The 
findings of this study highlight the importance of treatment compliance and the need to identify 
factors that may influence noncompliance. 
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 A placebo-controlled study by Johnson et al (1995) assessed the early clinical 
effectiveness of buprenorphine versus placebo in opioid-dependent patients. One-hundred and 
fifty patients were randomized to one of three treatment groups: buprenorphine 8 mg, 
buprenorphine 2 mg, and placebo. Patients received both individual and group counseling on a 
weekly basis. Primary outcome measures included the percentage of patients on initial 
dose (defined as the percentage of patients who remained on the dose to which they were 
randomized for each day of the 14-day treatment period) and the percentage of patients who 
requested a dose change (between day 6 and day 13). Secondary outcome measures included the 
percentage of opioid- and cocaine-positive urine samples and patient-reported dose adequacy 
(assessed by a response on a visual analog scale). 
 Results indicated that the percentage of patients who remained on their initial dose did 
not differ between the two buprenorphine treatment groups but differed from the placebo group, 
with a lower percentage in the placebo group. A higher percentage of patients in the placebo 
group requested a dose change compared to the buprenorphine 8 mg treatment group and 
buprenorphine 2 mg treatment group (65% compared to 32% and 27%, respectively). 
 An analysis of variance revealed a significant effect of dose and gender on the percentage 
of opioid- and cocaine-positive urine samples. Roughly 95%, 73%, and 67% of male patients in 
the placebo, buprenorphine 2 mg, and buprenorphine 8 mg treatment groups, respectively, had 
opioid-positive urine samples. Roughly 100%, 92%, and 89% of female patients in the placebo, 
buprenorphine 2 mg, and buprenorphine 8 mg treatment groups, respectively, had opioid-positive 
urine samples. In order to measure dose adequacy, a 100-mm visual analog scale was used. 
Patients were asked, “How well has this dose of medicine been holding you?” Results indicated 
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that the buprenorphine treatment groups differed from the placebo group but not from each other, 
with higher scores among buprenorphine-treated patients. 
 The results of this study indicate that buprenorphine is more effective than placebo in the 
treatment of opioid dependence. Patients who received buprenorphine remained on their initial 
dose longer and were less likely to request a dose change than patients who receive placebo. This 
may be interpreted as patients receiving buprenorphine finding their treatment more acceptable 
than patients receiving placebo; this is significant, as “the practical effectiveness of any treatment 
is limited by patient compliance” (Johnson, Eissenberg, Stitzer, Strain, Liebson, & Bigelow, 
1995). The authors note that an alternate interpretation is that those patients treated with placebo 
may have “detected the absence of an active drug effect” and consequently showed undesirable 
outcomes “as a consequence of low expectation of treatment efficacy” (Johnson et al., 1995). 
The observed effect on gender indicates that the early effectiveness of buprenorphine may be 
influenced by patient gender. 
Methadone. A double-blind, randomized study conducted by Strain et al (1999) 
compared the efficacy of moderate- versus high-dose methadone in opioid-dependent patients. 
Over the first week of treatment, all patients received 30 mg of methadone daily. Over the next 
five weeks, patients randomized to receive high-dose methadone had their dose increased by 
10 mg weekly, while patients randomized to receive moderate-dose methadone had their dose 
increased by 2 mg weekly. All patients received weekly individual and group therapy focused on 
relapse prevention. Efficacy was based primarily on the first 30 weeks of treatment; outcomes 
included self-reported illicit opioid use, urinalysis toxicology, and treatment retention. 
 Rates of opioid use during the treatment period decreased dramatically (approximately 
90%) compared to patients’ pre-treatment rates. During the second half of the stabilization phase 
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of the study, patients receiving high-dose methadone reported using opioids an average of one or 
fewer times per week, while patients receiving moderate-dose methadone reported using opioids 
an average of two to three times per week, constituting a significant difference between groups 
(p=0.01) and across time (p=0.001). Over the first 30 weeks of treatment, patients treated with 
high-dose methadone had a significantly lower rate of opioid-positive urine samples compared 
with patients treated with moderate-dose methadone (53% versus 61.9%, respectively). This 
effect was maintained through the detoxification phase of the study, with 46.4% of patients 
receiving high-dose methadone and 66.9% of patients receiving moderate-dose methadone 
having opioid-positive urine samples. There was no significant difference between groups in 
treatment retention. 
 The results of this study indicate that both high and moderate doses of methadone are 
“effective in maintaining patients in treatment and substantially decreasing rates of illicit opioid 
use” (Strain, Bigelow, Liebson, & Stitzer, 1999). While both treatment groups experienced a 
significant decrease in opioid use compared to the pre-treatment period, the high-dose 
methadone group experienced significantly greater decreases in opioid use compared to the 
moderate-dose methadone group. 
Methadone/Buprenorphine. A double-blind, randomized, controlled study conducted 
by Ling et al (1996) compared the effectiveness of methadone and buprenorphine in 
opioid-dependent patients. Two-hundred and twenty-five patients were randomized to receive 
either methadone 30 mg, methadone 80 mg, or buprenorphine 8 mg. Although the duration of the 
study was one year, efficacy was based on the first 26 weeks of treatment. Efficacy measures 
included days of retention in treatment, results of urinalysis for drugs of abuse, patient-reported 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 35 
measure of craving, and a checklist of opioid withdrawal symptoms. All patients received 
counseling throughout the study. 
 Over both the first 26 weeks of treatment and the entire one-year study duration, patients 
receiving methadone 80 mg had significantly better retention (52% at 26 weeks and 31% at 
one year) than the methadone 30 mg (40% at 26 weeks and 19% at one year) and 
buprenorphine (35% at 26 weeks and 20% at one year) groups. In regard to opioid use, each 
patient “had 1% more opioid-free scores reflecting opioid use after varying lengths of time 
during his or her tenure in the study” (Ling, Wesson, Charuvastra, & Klett, 1996). Over the first 
26 weeks of treatment, the mean ± standard deviation of these opioid-free scores was 61.9±31.6, 
44.6±33.5, and 44.5±36.0 for the methadone 80 mg, buprenorphine, and methadone 30 mg 
groups, respectively. Patients receiving methadone 80 mg experienced significantly more 
opioid-free days and less craving over both the first 26 weeks of treatment and the full year 
compared to patients receiving methadone 30 mg and buprenorphine. 
 The results of this study indicate that patients who receive 80 mg of methadone can be 
expected to “stay in treatment longer, use less opioids, and have less craving” than patients who 
receive 30 mg of methadone or 8 mg of buprenorphine (Ling et al., 1996). 
Naltrexone/Buprenorphine. A multicenter, randomized, open-label study by Lee et 
al (2018) explored the potential difference in relapse-free survival in patients with opioid use 
disorder receiving either XR-NTX or sublingual buprenorphine-naloxone (BUP-NX) over 
24 weeks of treatment. The primary objective of the study was to estimate the difference, if any, 
between the two treatments for relapse to regular opioid use (time to relapse). Secondary 
outcomes of the study included failure to initiate medication, opioid use during treatment, and 
adverse events, including overdoses. Five-hundred seventy patients at eight study sites across the 
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United States were randomized to receive either XR-NTX or BUP-NX. Relapse was defined as 
“the use of non-study opioids any time after day 20 post-randomization: at the start of 
four consecutive opioid use weeks or at the start of seven consecutive days of self-reported 
opioid use days” (Lee et al., 2018). Weekly assessments during the treatment phase of the study 
included the collection and analysis of patients’ urine toxicology samples. A so-called opioid use 
week was defined as “any week during which the participant reported at least one day of 
non-study opioid use with the timeline follow-back method, provided a urine toxicology sample 
that was positive for non-study opioids …, or did not provide a urine sample (missed visits or 
refusals)” (Lee et al., 2018). 
 More patients in the BUP-NX group were successfully inducted than in the XR-NTX 
group. For the primary intention-to-treat sample, the proportion of opioid-relapse events was 
185 (65%) of 283 patients for XR-NTX treatment versus 163 (57%) of 287 patients for BUP-NX 
treatment. Although the risk of relapse was lower in the BUP-NX group than in the XR-NTX 
group at the start of the study, the risk was not sustained. Subjective opioid craving decreased 
from baseline in both treatment groups. Although average opioid craving was initially less in the 
XR-NTX group than in the BUP-NX group, the rates had converged by week 24 of the treatment 
period. 
 The findings of this study indicate that it was more difficult to start XR-NTX treatment 
than BUP-NX treatment: 28% of patients dropped out of treatment before XR-NTX induction, 
while only 6% of patients dropped out before BUP-NX induction. Of these induction failures, 
nearly all experienced early relapse. In the intention-to-treat population of all randomized 
patients, XR-NTX was associated with lower relapse-free survival than BUP-NX, directly 
related to early induction failure. In the per-protocol population of all patients who successfully 
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initiated treatment, XR-NTX and BUP-NX were similarly effective. Fatal and non-fatal 
overdoses and other serious adverse events did not differ between the two treatment groups. 
Based on these findings, researchers concluded that, “if induction to either medication is 
successful, XR-NTX and BUP-NX were comparably effective and safe options” (Lee et al., 
2018). 
 A limitation of this study was overall treatment retention, which was between 43% and 
47% for the 24-week treatment period, which may be attributable to the fact that patients were 
recruited from inpatient detoxification units rather than outpatient settings. The findings of this 
study “afford providers, patients, and families a choice between agonist and antagonist therapies” 
(Lee et al., 2018). Although it was found that treatment with naltrexone was as efficacious as 
treatment with buprenorphine-naloxone, study findings highlight the risk of induction failure 
with naltrexone. 
Alcohol Dependence Studies 
Naltrexone. Naltrexone was first studied as a potential treatment for alcohol dependence 
in 1990. Volpicelli et al conducted a placebo-controlled study of 30 alcohol-dependent males, of 
which 14 received naltrexone and intensive psychosocial treatment. Their results indicated that 
those patients were “less likely to experience an alcoholic relapse and drank on fewer days than 
the 16 patients who received placebo” (O’Malley, 1996). Volpicelli et al and O’Malley et 
al (1992) went on to conduct two subsequent 12-week, double-blind, placebo-controlled studies 
with larger sample sizes. The first found that patients treated with naltrexone “had fewer 
drinking days, lower rates of relapse into heavy drinking, and reduced craving for alcohol” 
compared to patients treated with placebo (O’Malley, 1996). After sampling alcohol, 
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approximately 95% of placebo-treated patients met the criteria for a relapse, whereas only 
50% of naltrexone-treated patients experienced a relapse. 
Patients in the second study received either naltrexone or placebo in combination with 
one of two forms of psychotherapy (coping skills/relapse prevention therapy or supportive 
therapy). Compared with patients treated with placebo, those treated with naltrexone “consumed 
one-third of the number of drinks during treatment and drank on half as many days” (O’Malley, 
1996). Naltrexone-treated patients were more likely to remain abstinent from drinking and less 
likely to resume heavy drinking, with 34% and 43% of patients in the naltrexone/supportive 
therapy group and naltrexone/coping skills group, respectively, having relapsed by the end of the 
12-week treatment period (O’Malley, 1996). Alcohol craving was measured on a 20-point analog 
scale, with patients in the naltrexone treatment groups reporting lower levels of craving than 
those in the placebo groups (O’Malley, Jaffe, Chang, Schottenfeld, Meyer, & Rounsaville, 
1992). 
The results of this study support the efficacy of naltrexone in comparison to placebo and 
offer insight into the effects of specific psychosocial therapy. Patients who received supportive 
therapy were found to be least likely to initiate drinking, although patients who received coping 
skills/relapse prevention therapy were less likely to relapse than patients treated with naltrexone 
who did not receive coping skills therapy and less likely to relapse than patients treated with 
placebo. 
A meta-analysis of 19 double-blind, randomized, controlled clinical studies conducted by 
Jarosz et al (2013) compared the effectiveness of naltrexone versus placebo in alcohol-dependent 
patients. Only a small proportion of patients in two of the identified studies were abusing but not 
considered addicted to alcohol. All of the studies employed a treatment scheme that included 
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psychotherapy, although they differed in the type of psychotherapy used. The focus of the 
analysis was the results of 17 of the identified studies, each with a short-term treatment period of 
12 to 16 weeks. The results of three studies with medium- and long-term treatment periods 
(24 and 36 weeks; 52 weeks) were also presented. 
 There were statistically significant differences in favor of naltrexone for both abstinence 
and relapse; naltrexone increased the chance of abstinence (p=0.00182) and reduced the chance 
of relapse (p<0.0001) in alcohol-dependent patients. Additionally, statistically significant 
differences in favor of naltrexone were observed for alcohol craving scores, number of drinks per 
drinking day, percentage of days of abstinence, time to the first occurrence of relapse, and 
percentage of drinking days. In terms of safety, for short-term treatment periods, there were 
statistically significant differences in favor of naltrexone for rates of total withdrawal from 
treatment and withdrawal due to adverse events. There were no statistically significant 
differences related to efficacy and safety between naltrexone and placebo for medium- and 
long-term treatment periods. 
 The results of this meta-analysis indicate that naltrexone “enables the patients to keep at 
least partial control over alcohol consumption after a slip drinking episode, increases the 
patients’ control over alcohol urges, and improves cognitive resistance to thoughts about 
drinking,” all contributing to a significant decrease in the risk of relapse (Jarosz, Miernik, 
Wąchal, Walczak, & Krumpl, 2013). When combined with psychotherapy, naltrexone 
“significantly decreases the risk of destructive alcohol consumption” among alcohol-dependent 
patients (Jarosz et al., 2013). 
 A double-blind, placebo-controlled study conducted by Anton et al (1999) compared the 
effectiveness of naltrexone treatment versus treatment with placebo (identical-appearing capsule 
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containing 100 mg of riboflavin) in one-hundred and thirty-one alcohol-dependent patients. 
Primary variables for the evaluation of drinking outcome included time to first relapse, 
percentage of days abstinent, and number of drinks per drinking day. At the end of the 84-day 
treatment period, 62% of naltrexone-treated patients had not relapsed, while just 40% of 
placebo-treated patients had not experienced a relapse. The percentage of days abstinent was 
significantly higher in naltrexone-treated patients versus placebo-treated patients, and of those 
patients who experienced at least one drinking day, those treated with naltrexone had 
significantly fewer drinks compared to those treated with placebo. 
 Although the difference in time to first day of any drinking was not statistically 
significant between groups, the time between a first relapse or heavy drinking day and a 
second relapse or heavy drinking day was 14 days for naltrexone-treated patients and only 6 days 
for placebo-treated patients, supporting the concept that naltrexone “allows the alcoholic to keep 
at least partial control over alcohol consumption after a slip drinking episode” (Anton et al., 
1999). 
Acamprosate. Acamprosate was investigated as a potential relapse prevention therapy in 
alcohol-dependent patients in a double-blind, placebo-controlled study conducted by Tempesta 
et al (2000). Three-hundred and thirty patients were randomized to receive either acamprosate or 
placebo for a period of six months, followed by a three-month, medication-free follow-up period. 
The main outcome of the study was drinking behavior, which included abstinence or relapse for 
each period between assessment visits, cumulative abstinence duration, and uninterrupted 
(continued) abstinence (time to first relapse). Relapse was defined as any alcohol consumption; 
severity, based on consumption frequency and quantity of alcohol consumed, was measured as a 
secondary endpoint. 
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A difference in favor of acamprosate in the rate of abstinence and relapse was observed 
from day 30 onwards but was statistically significant only at days 150 and 180. The cumulative 
abstinence duration was significantly (p=0.016) longer in acamprosate-treated patients versus 
placebo-treated patients (110±77 days versus 89±77 days, respectively). Time to first relapse was 
significantly (p<0.01) longer with acamprosate treatment versus placebo treatment (135 days 
versus 58 days, respectively). Among patients who relapsed, frequency of consumption and 
quantity of alcohol consumed were significantly less in acamprosate-treated patients versus 
placebo patients, except at days 90 (for both frequency and quantity) and 120 (for quantity only). 
Ninety-five percent of patients who completed double-blind treatment entered and 
completed the three-month, medication-free follow-up period. During this period, the rate of 
abstinence among acamprosate-treated patients continued to be superior to that of 
placebo-treated patients, but by the end of the study, the difference between the groups had 
decreased to 49% in acamprosate patients and 41% in placebo patients. Cumulative abstinence 
duration continued to be significantly (p=0.028) longer among acamprosate-treated patients 
versus placebo patients throughout the entire nine-month study duration (155±114 days versus 
127±115 days, respectively). 
A randomized, double-blind, placebo-controlled study conducted by Sass et al (1996) 
assessed the effectiveness of acamprosate as an abstinence maintenance treatment in 
alcohol-dependent patients over one year. Two-hundred and seventy-two recently detoxified 
alcohol-dependent patients were randomized to receive either acamprosate or placebo over a 
48-week treatment period and were then followed over an additional 48-week period. Patients 
were assessed once every four weeks for the first 12 weeks of the study, then once every 
12 weeks thereafter. Patients’ self-reported drinking behavior was verified by the results of a 
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breathalyzer test, glutamyl transferase levels (twice the upper limit of normal which was 
considered suggestive of a relapse), and by interviewing a family member if feasible. These 
criteria and the physicians’ own impression had to be in agreement; otherwise, patients were 
considered not abstinent. Glutamyl transferase and other traditional biomarkers used to assess 
heavy drinking are discussed at the close of this chapter. 
The primary outcome of the study was based on absolute abstinence (no alcohol 
consumption) and assessed by several factors, including time to first drink, continuous 
abstinence, abstinent-relapse rates at individual visits, and cumulative abstinence duration. 
Alcohol craving was assessed by a 200-mm visual analog scale ranging from no desire (zero) to 
an uncontrollable desire (200). Medication compliance was assessed by urinalysis of 
acamprosate levels and counting of returned tablets. 
One-hundred and thirty-four patients remained in the study after one year. Throughout 
the treatment period, the mean ± standard deviation number of days to first relapse was 
165.2±143.8 days in acamprosate-treated patients and 112.3±126.5 days in placebo-treated 
patients. At the end of the treatment period, 44.8% of acamprosate-treated patients who had 
completed the study had never had a relapse, while just 25.3% of placebo-treated patients had 
never had a relapse. At the first visit at which patients received medication (week 4), 72% of 
acamprosate-treated patients and 61% of placebo-treated patients were abstinent. At the last visit 
at which patients received medication (week 48), 43% of acamprosate-treated patients and 
21% of placebo-treated patients were abstinent. There was a statistically significant difference in 
cumulative abstinence duration, or total number of abstinent days, between the two treatment 
groups. The mean ± standard deviation cumulative abstinence duration was 224.62±136.61 days, 
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or 62.4% days abstinent, in acamprosate-treated patients; and was 162.03±132.19 days, or 
45.3% days abstinent, in placebo-treated patients. 
One-hundred and four patients completed the entire 96-week study period. The 
progression between the two treatment groups was similar: 5% to 6% of patients in each 
treatment group had at least one relapse during the follow-up period. At the end of the follow-up 
period, 39.9% of the remaining acamprosate-treated patients and 17.3% of the remaining 
placebo-treated patients had never had a relapse. Over the two-year study period, the 
mean ± standard deviation cumulative abstinence duration was 387.14±280.52 days, or 
54% days abstinent, in acamprosate treated patients; and was 250.95±244.63 days, or 35% days 
abstinent in placebo-treated patients. 
The authors noted that the significant difference in abstinence rates between the 
two treatment groups throughout the follow-up period and the lack of rebound phenomenon may 
suggest that “at or before termination of study medication, the conditions of the patients were 
sufficiently stabilized to control possible rebound relapse” (Sass et al., 1996). They suggested 
that another potential explanation is that “the pharmacodynamic effect or the need for 
acamprosate could have diminished over time, as neurotransmitters were physiologically adapted 
to the conditions of prolonged abstinence” (Sass et al., 1996). These results support the 
long-term efficacy of acamprosate, even after regular treatment with the medication has ceased. 
Disulfiram. A study by Specka et al (2014) assessed the efficacy, tolerability, and safety 
of disulfiram treatment for relapse prevention in alcohol-dependent patients undergoing opioid 
maintenance treatment. Patient-reported alcohol consumption was verified by blood samples, 
breath alcohol analyses, and urine drug screenings. Of the 29 patients included in the study, most 
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received methadone, and a few received buprenorphine. Disulfiram was given to patients 
immediately before their respective opiate agonist was dispensed. 
 During the treatment period, 17 (58.6%) patients showed evidence of at least one episode 
of alcohol consumption. The estimated median time to first consumption during disulfiram 
treatment was 111 days, and the estimated median time to first alcohol consumption or 
termination of disulfiram treatment was 64 days. Of 29 patients, 6 (20.7%) completed the study 
and did not show evidence of alcohol consumption. 
 This study is unique in that it assessed disulfiram treatment for alcohol relapse prevention 
in patients who were also undergoing treatment for opioid dependence. In addition to heavy 
alcohol consumption, most of these patients used other drugs, had infections of hepatitis C or 
human immunodeficiency virus, and/or exhibited signs of underlying psychiatric disorders. 
Nearly half of patients receiving disulfiram completed six months of the treatment period, and 
while just 20% of the study population completed the full treatment period of nine months 
without evidence of alcohol consumption, “the rate for alcohol use was generally low, and 
treatment compliance was high” (Specka, Heilmann, Lieb, & Scherbaum, 2014). 
 Because heavy alcohol use in patients receiving opioid maintenance treatment is 
associated with premature treatment discontinuation and presents a major health risk, alcohol 
relapse prevention during opioid maintenance treatment is vital. Although disulfiram treatment 
within this setting may be complicated by the need of close supervision and adverse event 
monitoring, the results of this study indicate the effectiveness of disulfiram in relation to 
drinking outcomes. 
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 A systematic literature review by Jørgensen et al (2011) included eleven randomized 
controlled studies assessing disulfiram treatment in patients with alcohol use disorder. 
Three studies compared disulfiram with placebo, two compared disulfiram with a control, and 
six compared disulfiram with other abstinence-supportive drugs. In ten of the eleven studies, 
disulfiram treatment was supplemented with either cognitive therapy, psychotherapy, or alcohol 
counseling. Methods of ensuring compliance varied but overall relied upon patient self-report 
supplemented by relative feedback (in six studies) and pill/bottle counts, urine drug screenings, 
blood tests, and/or breath analyzers (in six studies). Across all studies, the median compliance 
rate was 85%, and the median follow-up rate was 93%. 
The six studies that compared disulfiram with other abstinence-supportive drugs had 
durations of six to 12 months. Four studies reported significantly more abstinent patients 
receiving disulfiram (respectively, 86% versus 44%, 88% versus 46%, 90% versus 56%, and 
79% versus 52%). All six studies, as well as one additional study, showed significantly more 
days until relapse in disulfiram-treated patients. The three studies that compared disulfiram with 
placebo had durations of three, 12, and 12 months, respectively. Only the short-term study 
reported significantly more abstinent patients among those who received disulfiram (54%) versus 
placebo (15%). One of the two 12-month studies reported significantly fewer drinking days in 
patients treated with disulfiram who had completed all follow-up interviews. 
The two studies that compared disulfiram with a control (no treatment) differed in their 
results. One reported a significant difference in abstinence in disulfiram-treated patients, as all 
20 treated patients remained abstinent during the three-week treatment period, while those who 
did not receive treatment continued to drink. The other study reported no significant difference in 
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abstinence, number of days until relapse, or alcohol-free days after six months in patients who 
received disulfiram versus patients who did not receive treatment. 
The authors found that disulfiram had a significant effect on abstinence in six of the 
included studies. Four studies did not show this effect but did not show that other treatment was 
significantly better than disulfiram. Five studies showed that disulfiram-treated patients 
experienced an increased number of days before relapse compared to other treatments/no 
treatment. 
Naltrexone/Acamprosate. A systematic review and meta-analysis conducted by Jonas et 
al (2014) assessed the benefits and harms of various FDA-approved medications for adults with 
alcohol use disorders. One-hundred and twenty-two randomized controlled studies and 
one cohort study, with a total of 22,803 patients, were included, of which 44 were of 
naltrexone (oral and injectable), 22 of acamprosate, and four of disulfiram. 
 Results demonstrate that treatment with naltrexone and acamprosate was associated with 
improvement in alcohol consumption outcomes. While both oral naltrexone and acamprosate 
were associated with improved outcomes in return to any drinking (16 studies), only oral 
naltrexone was associated with an improvement in return to heavy drinking (19 studies). There 
were no statistically significant associations between injectable naltrexone and return to either 
any drinking or heavy drinking, but there was an association between injectable naltrexone and a 
reduction in heavy drinking days (two studies). 
 The results of this analysis indicate that, in patients with alcohol use disorders, treatment 
with several medications, especially oral naltrexone and acamprosate, results in improved 
alcohol consumption outcomes when used in conjunction with psychosocial interventions. 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 47 
 The COMBINE study, by Anton et al (2006), is the largest pharmacotherapy clinical 
study on alcoholism conducted in the United States to-date. Over a three-year period, 
1,383 alcohol-dependent patients were randomized to one of nine treatment groups, eight of 
which (n=1,226) received medical management, a nine-session intervention focused on 
enhancing medication adherence and alcohol abstinence. Four of these groups (n=619) also 
received more intensive counseling (combined behavioral intervention, or CBI) delivered by 
alcoholism treatment specialists. Patients in all eight groups received either active/placebo 
naltrexone or active/placebo acamprosate, yielding four medication conditions (placebo, 
acamprosate, naltrexone, and acamprosate plus naltrexone) within each level of behavioral 
counseling (CBI versus no CBI). A ninth group (n=157) received CBI alone, without medication 
or medical management. 
 Primary treatment outcomes included percentage of days abstinent and time to first heavy 
drinking day; and secondary treatment outcomes included number of drinks per drinking day, 
heavy drinking days per month, time to first drink, and craving as assessed by the 
Obsessive-Compulsive Drinking Scales. Patients’ alcohol consumption and craving were 
assessed nine times during the 16-week treatment period, as well as at 26, 52, and 68 weeks after 
randomization. 
 All treatment groups showed a substantial reduction in drinking. During treatment, 
patients receiving naltrexone and medical management, placebo with CBI and medical 
management, or both naltrexone and CBI with medical management had a higher percentage of 
days abstinent (80.6%, 79.2%, and 77.1%, respectively) than patients receiving placebo and 
medical management only (75.1%). The three-factor interaction of naltrexone, acamprosate, and 
CBI was not significant in regard to percentage of days abstinent; however, the two-factor 
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interaction of naltrexone and CBI was significant (p=0.009). Examination of the least squares 
means associated with this interaction showed that patients receiving neither naltrexone nor CBI 
had the fewest abstinent days, while patients receiving either naltrexone or CBI had the most 
abstinent days. Treatment with naltrexone plus CBI did not show any incremental benefit over 
treatment with naltrexone or CBI alone. 
 In regard to time to first heavy drinking day, there were no significant main effects or 
interactions involving acamprosate. There was, however, a significant main effect of naltrexone 
(p=0.02). Patients receiving naltrexone demonstrated, on average, a lower risk of heavy drinking 
than patients receiving placebo. Patients who did not receive naltrexone or CBI fared worst. 
 The results of the study indicate that patients receiving medical management who also 
received either CBI or naltrexone had better treatment outcomes than other patients. The authors 
acknowledged that the lack of acamprosate efficacy was surprising but noted that a salient 
difference between this study and others was the fact that inclusion in this study required only 
four days of abstinence. Over the one-year follow-up period, consistent with previous studies, 
differential treatment effects dissipated over time. The authors stated that medical management 
with naltrexone within a primary care setting “could greatly extend patient access to effective 
treatment” (Anton et al., 2006). 
Naltrexone/Acamprosate/Disulfiram. A randomized, multicenter, open-label study 
conducted by Laaksonen et al (2007) compared the efficacy of naltrexone, acamprosate, and 
disulfiram in the treatment of alcohol dependence. Two-hundred and forty-three patients were 
randomized to receive treatment with either naltrexone, acamprosate, or disulfiram over a 
52-week treatment period. For the first 12 weeks of the treatment period, patients were to 
continue taking a daily dose of study medication; during the subsequent weeks, patients were to 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 49 
take a dose of the study medication only in a “craving situation,” in which they perceived that 
their likelihood of drinking was high. Throughout the study, patients also received a brief, 
manual-based cognitive-behavioral intervention. 
 The primary outcome measures of the study included time to first heavy drinking day 
(consumption of five or more drinks for men and four or more drinks for women or being 
intoxicated during the study visit) during the first three months of treatment and time to first 
drinking day after medication started. Secondary outcome measures included number of 
abstinent days per week; average weekly alcohol intake; and Alcohol Use Disorder Identification 
Test (AUDIT), Severity of Alcohol Dependence Data (SADD), and quality of life measures. 
Compliance was verified by pill count at each study visit and patient diary records. 
 During the first 12 weeks of treatment, there were statistically significant differences in 
time to first heavy drinking day, time to first drinking day, and number of abstinent days per 
week in favor of disulfiram compared to naltrexone and acamprosate. The mean ± standard 
deviation time to first heavy drinking day was 46.6±27.5 days, 22.0±22.0 days, and 
17.6±22.0 days for disulfiram-, naltrexone-, and acamprosate-treated patients, respectively. The 
mean ± standard deviation time to first drinking day was 30.4±27.8 days, 16.2±20.2 days, and 
11.4±17.0 days for disulfiram-, naltrexone-, and acamprosate-treated patients, respectively. The 
mean ± standard deviation number of abstinent days per week was 6.3±0.9 days, 4.6±2.0 days, 
and 4.5±2.1 days for disulfiram-, naltrexone-, and acamprosate-treated patients, respectively. 
 During the targeted medication period of the study (weeks 13 to 52), there were no 
significant differences between the three treatment groups in time to first heavy drinking day or 
time to first drinking day, but disulfiram-treated patients experienced significantly more 
abstinent days than naltrexone- and acamprosate-treated patients. The time to first drinking day 
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over the 52-week treatment period was significantly longer in disulfiram-treated patients 
compared to naltrexone- and acamprosate-treated patients. The degree of severity of alcohol 
dependence indicators as measured by AUDIT and SADD scores demonstrated a significant 
reduction in all three treatment groups; at week 26, naltrexone-treated patients had significantly 
better SADD scores than disulfiram- and acamprosate-treated patients. There was a statistically 
significant improvement in quality of life scores over the 52-week treatment period in all 
three treatment groups. 
 The psychotherapeutic intervention included in this study involved the use of a manual 
based on cognitive-behavioral principles that provided patients with various assignments meant 
to “facilitate the self-regulation of drinking and to assist the patient in achieving a healthier 
lifestyle” (Laaksonen, Koski-Jännes, Salaspuro, Ahtinen, & Alho, 2007). The manual and its 
assignments were discussed with the physician at each study visit, contributing to a more 
comprehensive doctor-patient interaction. Although the study did not evaluate the effects of this 
intervention, its value is evident in the fact that 79.4% of patients reported that they found the 
treatment to be useful. 
 The results of this study demonstrate the effectiveness of naltrexone, acamprosate, and 
disulfiram in reducing heavy drinking, reducing alcohol craving, and improving quality of life in 
alcohol-dependent patients, as well as the superiority of disulfiram when compared to naltrexone 
and acamprosate. Additionally, the use of a manual-based cognitive-behavioral intervention 
highlights the importance of incorporating psychotherapy into a comprehensive treatment 
approach. 
Biomarkers of heavy drinking. As demonstrated in the study by Sass et al (1996), 
gamma-glutamyl transferase (or GGT) levels are a common biomarker used to assess heavy 
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drinking. GGT is a glycoenzyme found in the endothelial cell membranes of some organs that 
appears to mediate glutathione metabolism. An elevated serum GGT level “remains the most 
widely used marker of alcohol abuse” (Allen, Sillanaukee, Strid, & Litten, 2004). 
 Other common biomarkers of heavy drinking include aspartate aminotransferase and 
alanine aminotransferase levels. In alcohol-dependent patients, enhanced levels of these serum 
aminotransferases reflect liver damage. Additionally, elevated erythrocyte macrocytic volume is 
common in alcohol-dependent patients and “results directly from the effect of alcohol on 
erythroblast development and persists as long as drinking continues” (Allen et al., 2004). Lastly, 
transferrin, a glycoprotein metabolized in the liver, contains two carbohydrate residues and may 
be attached to six sialic acid moieties; with heavy alcohol intake, the moieties can lose 
carbohydrate content, so carbohydrate-deficient transferrin levels are a common biomarker of 
heavy drinking. 
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Chapter Three: Methodology 
Methods 
For the purpose of this paper, several methods were used in order to ensure a high-quality 
and comprehensive review of the current literature on FDA-approved pharmacological therapies 
for relapse prevention in and treatment of opioid and alcohol addiction. These methods were also 
used to gather additional relevant information on opioid and alcohol addiction in general, relapse 
and relapse prevention, addiction therapies, and various statistics related to the disease burden of 
addiction and substance abuse. 
 The primary method of obtaining research sources for this literature review was the 
utilization of online databases and search engines, including PubMed and Google Scholar. These 
provided a wealth of peer-reviewed journal articles, including clinical studies, meta-analyses, 
and systematic reviews. The keywords used in such searches included “pharmacological 
therapies,” “pharmacological agents,” “relapse prevention,” “opioid,” “alcohol,” “opioid 
addiction,” “alcohol addiction,” “naltrexone,” “buprenorphine,” “methadone,” “acamprosate,” 
“disulfiram,” “addiction relapse,” “medication-assisted therapy,” “addiction therapy,” “clinical 
trial,” “addiction relapse,” etc. 
Source Selection 
 Several factors were considered when selecting sources, including year of publication, 
extent of generalizability, perceived quality of study, type of study, and specificity of source 
content. 
 Academic journals on the topic of substance abuse and addiction, including The Journal 
of Addiction Medicine, The American Journal of Drug and Alcohol Abuse, The Journal of 
Addiction Research and Therapy, The American Journal of Drug and Alcohol Abuse, The 
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American Journal on Addictions, Substance Use and Misuse, and The Journal of Substance 
Abuse Treatment, were also searched for potential sources. 
 Government-affiliated websites, such as the National Institutes of Health, the National 
Institute on Drug Abuse, Centers for Disease Control and Prevention, and U.S. Department of 
Health and Human Services, were used to collect information on opioid and alcohol addiction, 
their related public health and economic burden, and statistical figures on deaths and economic 
costs in the United States. 
Inclusion and Exclusion Criteria 
 In order to present the most robust data, the inclusion of randomized, double-blind, 
controlled studies was prioritized. Only scholarly sources (i.e., those that are academic in nature, 
peer-reviewed, etc.) were considered for inclusion in order to present data and information of the 
highest quality. 
Sources were typically excluded if the year of publication was over 20 years ago (with 
some exceptions), the results of the study were likely not generalizable to the wider population, 
the size of the study population was too small, the study was not conducted in humans, or the 
content of the source was not specific to the topic of this paper. Several clinical studies that were 
conducted over 20 years ago were included in the literature review, as clinical research on 
addiction pharmacotherapies has largely shifted its focus from more veteran medications to more 
recently approved medications. Additionally, because disulfiram, methadone, naltrexone for 
opioid dependence, and naltrexone for alcohol dependence were approved in 1951, 1972, 1984, 
and 1995, respectively, much of the research investigating these medications was conducted 
prior to the last decade. Because the physiology of opioid and alcohol use disorders has not 
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changed, the findings of older clinical studies hold just as much significance as those of more 
recent studies. 
Because the focus of the literature review was on the FDA-approved pharmacological 
agents naltrexone, buprenorphine, methadone, acamprosate, and disulfiram, studies on other 
medications were typically excluded. 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 55 
Chapter Four: Results 
 This chapter highlights the key efficacy and safety results of a number of the clinical 
studies presented in Chapter Two (excluding meta-analyses that examined several studies and 
those that did not provide specific numerical data). A more detailed discussion of these studies 
and their results is provided in Chapter Two. 
Efficacy of Current Pharmacological Therapies: Key Results 
Opioid dependence studies. 
Naltrexone Study #1. A double-blind, placebo-controlled, randomized, multicenter study 
conducted by Krupitsky et al (2011) explored the efficacy, safety, and patient-reported outcomes 
of injectable XR-NTX in patients with opioid dependence (see Tables 1 and 2). 
Table 1 
Naltrexone Study #1: Overview 
Element Description 
Study design Double-blind, placebo-controlled, randomized, multicenter 
Indication Opioid dependence disorder 
Investigational drug Naltrexone (extended release) (380 mg) 
Placebo/control Placebo 
Treatment arms XR-NTX (n=126), placebo (n=124) 
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Study population Males and females aged ≥18 years with opioid dependence 
disorder, completing inpatient opioid detoxification 
(≤30 days), off opioids for ≥7 days 
Number of subjects 250 
Study duration 24-week treatment period 
Location(s) Russia (13 clinical sites) 
Psychosocial intervention Biweekly counseling sessions (12) 
XR-NTX=extended-release naltrexone. 
Source: Krupitsky et al., 2011. 
Table 2 
Naltrexone Study #2: Key Results 
Endpoint/Outcome XR-NTX (n=126) Placebo (n=124) 
Proportion of weeks of confirmed abstinence 90.0% 35.0% 
Patients with total confirmed abstinence 45 (35.7%) 28 (22.6%) 
Self-reported opioid-free days 99.2% 60.4% 
Opioid craving scores -10.1 -0.7 
Number of days of retention >168 96 
Relapse to physiological opioid dependence 1 17 
XR-NTX=extended-release naltrexone. 
Note. Opioid craving score is the mean change in visual analog scale score from baseline. Relapse to 
physiological opioid dependence is the number of participants with positive naloxone challenge test. 
Source: Krupitsky et al., 2011. 
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Naltrexone Study #2. An open-label, randomized, controlled effectiveness study 
conducted by Lee et al (2016) explored the efficacy of extended-release naltrexone (brand name 
Vivitrol) in reducing opioid relapse compared with “treatment as usual” in opioid-dependent 
criminal justice system offenders (see Tables 3 and 4). 
Table 3 
Naltrexone Study #2: Overview 
Element Description 
Study design Open-label, randomized, multicenter, controlled effectiveness 
Indication Opioid dependence disorder 
Investigational drug Naltrexone (extended release) (380 mg) 
Placebo/control Usual treatment (brief counseling and referrals for community 
treatment programs) 
Treatment arms Naltrexone (n=153), usual treatment (n=155) 
Study population Community-dwelling adult volunteers who had been 
incarcerated and who had a history of opioid dependence 
aged 18 to 60 years 
Number of subjects 308 
Study duration 24-week treatment period 
Location(s) United States (5 clinical sites) 
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Psychosocial intervention Medical management counseling 
Source: Lee et al., 2016. 
Table 4 
Naltrexone Study #2: Key Results 
Endpoint/Outcome XR-NTX (n=153) Usual treatment (n=155) 
Time to relapse, weeks 10.5 5.0 
Number of participants with a relapse event 66 (43%) 99 (64%) 
Rate of opioid-negative urine samples 
during treatment period 
74% 56% 
Rate of opioid-negative urine samples 
one year after treatment 
46% 46% 
Overdose events 0 7 
XR-NTX=extended-release naltrexone. 
Source: Lee et al., 2016. 
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Buprenorphine Study #1. A study by Tkacz et al (2011) examined the effects of 
buprenorphine compliance on the rates of relapse in opioid-dependent patients (see Tables 5 
and 6). 
Table 5 
Buprenorphine Study #1: Overview 
Element Description 
Study design Observational 
Indication Opioid dependence disorder 
Investigational drug Buprenorphine 
Placebo/control None 
Treatment arms Buprenorphine, buprenorphine plus HereToHelp™ (disease 
management program) 
Study population Opioid dependence patients 
Number of subjects 703 
Study duration 3 months 
Location(s) United States 
Psychosocial intervention HereToHelp™ (disease management program) 
Source: Tkacz et al., 2011. 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 60 
Table 6 
Buprenorphine Study #1: Key Results 
Characteristic Did not relapse within 
3 months (n=561) 
Relapsed within 
3 months (n=142) 
Buprenorphine compliant 517 (92.2) 75 (52.8) 
Source: Tkacz et al., 2011. 
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Buprenorphine Study #2. A placebo-controlled study by Johnson et al (1995) assessed 
the early clinical effectiveness of buprenorphine versus placebo in opioid-dependent patients (see 
Tables 7 and 8). 
Table 7 
Buprenorphine Study #2: Overview 
Element Description 
Study design Randomized, double-blind, placebo-controlled, parallel-group 
Indication Opioid dependence disorder 
Investigational drug Buprenorphine 
Placebo/control Placebo 
Treatment arms Buprenorphine 8 mg (n=30), buprenorphine 2 mg (n=60), 
placebo (n=60) 
Study population Male and female volunteers admitted to a short-term opioid 
treatment research clinic 
Number of subjects 150 
Study duration 14 days (part one of a two-part study) 
Location(s) United States (1 clinical site) 
Psychosocial intervention Weekly individual and group therapy 
Source: Johnson et al., 1995. 
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Table 8 
Buprenorphine Study #2: Key Results 
Endpoint/Outcome Bup 8 mg (n=30) Bup 2 mg (n=60) Placebo (n=60) 
Percentage of patients on initial dose 
at day 14 
~52% ~61% ~26% 
Percentage of patients requesting a 
dose change 
32% 27% 65% 
Percentage of urine specimens 
positive for opioids (males) 
~67% ~73% ~95% 
Percentage of urine specimens 
positive for opioids (females) 
~89% ~92% ~100% 
Dose adequacy (VAS score) 20 17 7 
Bup=buprenorphine; VAS=visual analog scale. 
Source: Johnson et al., 1995. 
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Methadone Study. A double-blind, randomized study conducted by Strain et al (1999) 
compared the efficacy of moderate- versus high-dose methadone in opioid-dependent patients 
(see Tables 9 and 10). 
Table 9 
Methadone Study: Overview 
Element Description 
Study design Randomized, double-blind 
Indication Opioid dependence disorder 
Investigational drug Methadone (moderate and high doses) 
Placebo/control None 
Treatment arms Methadone 40-50 mg (n=97), methadone 80-100 mg (n=95) 
Study population Patients aged ≥18 years, current intravenous opioid 
dependence 
Number of subjects 192 
Study duration 40-week treatment period 
Location(s) United States (1 clinical site) 
Psychosocial intervention Weekly individual and group therapy focused on relapse 
prevention 
Source: Strain et al., 1999. 
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Table 10 
Methadone Study: Key Results 
Endpoint/Outcome High dose (n=95) Moderate dose (n=97) 
Self-reported illicit opioid use (second 
half of stabilization phase) 
≤1 time/week 2-3 times/week 
Rate of opioid-positive urine samples 
(maintenance phase) 
53.0% 61.9% 
Treatment retention (through stable 
dosing phase), days 
159 157 
Rate of opioid-positive urine samples 
(detoxification phase) 
46.4% 66.9% 
Source: Strain et al., 1999. 
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Methadone/Buprenorphine Study. A double-blind, randomized, controlled study 
conducted by Ling et al (1996) compared the effectiveness of methadone and buprenorphine in 
opioid-dependent patients (see Tables 11 and 12). 
Table 11 
Methadone/Buprenorphine Study: Overview 
Element Description 
Study design Randomized, double-blind 
Indication Opioid dependence disorder 
Investigational drug Methadone, buprenorphine 
Placebo/control None 
Treatment arms Methadone 30 mg (n=75), methadone 80 mg (n=75), 
buprenorphine 8 mg (n=75) 
Study population Patients seeking treatment at an outpatient treatment clinic 
aged 18 to 65 years 
Number of subjects 225 
Study duration 52 weeks 
Location(s) United States (1 clinical site) 
Psychosocial intervention Weekly individual counseling sessions (not required) 
Source: Ling et al., 1996. 
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Table 12 
Methadone/Buprenorphine Study: Key Results 
Endpoint/Outcome M80 (n=75) M30 (n=75) Bup (n=75) 
Percentage of patients completing 26 weeks 
of treatment 
52% 40% 35% 
Percentage of patients completing 52 weeks 
of treatment 
31% 19% 20% 
Opioid-free scores (mean±SD) 61.9±31.6 44.5±36.0 44.6±33.5 
Bup=buprenorphine; M30=methadone 30 mg; M80=methadone 80 mg; SD=standard deviation. 
Source: Ling et al., 1996. 
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Naltrexone/Buprenorphine Study. A multicenter, randomized, open-label study by 
Lee et al (2018) explored the potential difference in relapse-free survival in patients with opioid 
use disorder receiving either XR-NTX or sublingual buprenorphine-naloxone over 24 weeks of 
treatment (see Tables 13 and 14). 
Table 13 
Naltrexone/Buprenorphine Study: Overview 
Element Description 
Study design Randomized, open-label, controlled, comparative 
effectiveness, multicenter 
Indication Opioid dependence disorder 
Investigational drug Naltrexone (extended release), buprenorphine-naloxone 
Placebo/control None 
Treatment arms XR-NTX (n=283), BUP-NX (n=287) 
Study population Patients aged ≥18 years, had used non-prescribed opioids in 
past 30 days 
Number of subjects 570 
Study duration 24 weeks 
Location(s) United States (8 clinical sites) 
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Psychosocial intervention Standard medical management; additional voluntary ancillary 
psychosocial counseling was recommended and available 
BUP-NX=buprenorphine-naloxone; XR-NTX=extended-release naltrexone. 
Source: Lee et al., 2018. 
Table 14 
Naltrexone/Buprenorphine Study: Key Results 
Endpoint/Outcome XR-NTX (n=283) BUP-NX (n=287) 
Proportion of relapse events 185 (65%) 163 (57%) 
Proportion of patients successfully inducted onto 
an initial dose 
204 (72%) 270 (94%) 
Number of weekly opioid-negative urine samples 
(range 0 to 24 weeks) 
4 10 
Number of self-reported opioid-abstinent days 
(range 0 to 144 days) 
39 81 
BUP-NX=buprenorphine-naloxone; XR-NTX=extended-release naltrexone. 
Source: Lee et al., 2018. 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 69 
Alcohol dependence studies. 
Naltrexone Study #3. A randomized, double-blind, placebo-controlled study by 
O’Malley et al. (1992) assessed the efficacy of naltrexone versus placebo, in which patients 
received either naltrexone or placebo in combination with one of two forms of psychotherapy 
(coping skills/relapse prevention therapy or supportive therapy) (see Tables 15 and 16). 
Table 15 
Naltrexone Study #3: Overview 
Element Description 
Study design Randomized, double-blind, placebo-controlled 
Indication Alcohol use disorder 
Investigational drug Naltrexone 
Placebo/control Placebo 
Treatment arms Naltrexone + coping skills therapy (n=29), 
naltrexone + supportive therapy (n=23), placebo + coping 
skills therapy (n=25), placebo + supportive therapy (n=27) 
Study population Alcohol-dependent males and females 
Number of subjects 97 
Study duration 12 weeks 
Location(s) United States (1 clinical site) 
Psychosocial intervention Coping skills therapy, supportive therapy 
Source: O’Malley et al., 1992. 
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Table 16 
Naltrexone Study #3: Key Results 
Endpoint/Outcome Naltrexone/ 
Coping skills 
(n=24) 
Naltrexone/ 
Supportive 
(n=22) 
Placebo/ 
Coping skills 
(n=24) 
Placebo/ 
Supportive 
(n=27) 
Abstention 28% 61% 21% 19% 
Percentage (SE) drinking 
days 
4.2±1.9 4.3±2.3 10.4±1.9 9.4±1.8 
Total number of drinks, 
mean±SE 
12.8±9.1 14.6±9.4 46.6±9.0 29.4±8.6 
Craving past week, mean±SE 3.1±0.8 4.4±0.9 5.3±0.8 4.7±0.8 
SE=standard error. 
Source: O’Malley et al., 1992. 
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Naltrexone Study #4. A double-blind, placebo-controlled study conducted by Anton et 
al (1999) compared the effectiveness of naltrexone treatment versus treatment with placebo 
(identical-appearing capsule containing 100 mg of riboflavin) in one-hundred and 
thirty-one alcohol-dependent patients (see Tables 17 and 18). 
Table 17 
Naltrexone Study #4: Overview 
Element Description 
Study design Randomized, placebo-controlled 
Indication Alcohol use disorder 
Investigational drug Naltrexone 
Placebo/control Placebo 
Treatment arms Naltrexone + CBT (n=68), placebo + CBT (n=63) 
Study population Recently abstinent alcohol-dependent outpatients aged 21 to 
65 years 
Number of subjects 131 
Study duration 12 weeks 
Location(s) United States 
Psychosocial intervention CBT 
CBT=cognitive behavioral therapy. 
Source: Anton et al., 1999. 
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Table 18 
Naltrexone Study #4: Key Results 
Endpoint/Outcome Naltrexone/CBT (n=68) Placebo/CBT (n=63) 
Percentage of days abstinent (mean, SD) 90, 18.9 82, 22.9 
Time to first drink, days 48, 33 40, 40 
Time to relapse, days 60, 33 48, 32 
Analog craving scale score 16.3, 16.5 18.2, 18.7 
CBT=cognitive behavioral therapy; SD=standard deviation. 
Source: Anton et al., 1999. 
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Acamprosate Study #1. Acamprosate was investigated as a potential relapse prevention 
therapy in alcohol-dependent patients in a double-blind, placebo-controlled study conducted by 
Tempesta et al (2000) (see Tables 19 and 20). 
Table 19 
Acamprosate Study #1: Overview 
Element Description 
Study design Randomized, double-blind, placebo-controlled, multicenter 
Indication Alcohol use disorder 
Investigational drug Acamprosate 
Placebo/control Placebo 
Treatment arms Acamprosate (n=164), placebo (n=166) 
Study population Male and female alcohol-dependent patients aged 18 to 
65 years 
Number of subjects 330 
Study duration 6-month treatment period, 3-month follow-up period 
Location(s) Italy (18 clinical sites) 
Psychosocial intervention Weekly medical counseling on alcohol-related problems; 
individual behavior-oriented supportive counseling and 
AA were available 
AA=Alcoholics Anonymous. 
Source: Tempesta et al., 2000. 
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Table 20 
Acamprosate Study #1: Key Results 
Endpoint/Outcome Acamprosate (n=164) Placebo (n=166) 
Percentage of patients abstinent (day 30) 68.3% 56.0% 
Percentage of patients abstinent (day 180) 57.9% 45.2% 
Cumulative abstinence duration, days 110±77 89±77 
Median time of abstinence prior to first 
relapse, days 
135 58 
Source: Tempesta et al., 2000. 
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Acamprosate Study #2. A randomized, double-blind, placebo-controlled study conducted 
by Sass et al (1996) assessed the effectiveness of acamprosate as an abstinence maintenance 
treatment in alcohol-dependent patients over one year (see Tables 21 and 22). 
Table 21 
Acamprosate Study #2: Overview 
Element Description 
Study design Randomized, double-blind, placebo-controlled, multicenter 
Indication Alcohol use disorder 
Investigational drug Acamprosate 
Placebo/control Placebo 
Treatment arms Acamprosate (n=136), placebo (n=136) 
Study population Newly detoxified alcohol-dependent patients, abstinent 
for ≥14 to ≤28 days 
Number of subjects 272 
Study duration 48-week treatment period, 48-week follow-up period 
Location(s) Germany (12 clinical sites) 
Psychosocial intervention Counseling or psychotherapy (not standardized between 
centers) 
Source: Sass et al., 1996. 
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Table 22 
Acamprosate Study #2: Key Results 
Endpoint/Outcome Acamprosate (n=136) Placebo (n=136) 
Number of days to first relapse (treatment 
period) (mean±SD) 
165.2±143.8 112.3±126.5 
Percentage of patients who completed 
treatment who never had a relapse 
44.8% 25.3% 
Percentage of patients abstinent at last 
medication visit 
43% 21% 
Cumulative abstinence duration, days 
(treatment period) (mean±SD, %) 
224.62±136.61, 
62.4% 
162.03±132.19, 
45.3% 
SD=standard deviation. 
Source: Sass et al., 1996. 
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Disulfiram Study. A study by Specka et al (2014) assessed the efficacy, tolerability, and 
safety of disulfiram treatment for relapse prevention in alcohol-dependent patients undergoing 
opioid maintenance treatment (see Tables 23 and 24). 
Table 23 
Disulfiram Study: Overview 
Element Description 
Study design Prospective, observational 
Indication Alcohol use disorder 
Investigational drug Disulfiram 
Placebo/control None 
Treatment arms Disulfiram (n=29) 
Study population Patients in outpatient opioid maintenance treatment 
Number of subjects 29 
Study duration Up to 6 months 
Location(s) Germany (2 clinical sites) 
Psychosocial intervention Psychotherapeutic treatment of psychiatric disorders; regular 
contact with a social worker 
Source: Specka et al., 2014. 
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Table 24 
Disulfiram Study: Key Results 
Endpoint/Outcome Disulfiram (n=29) 
Median time until first alcohol consumption during 
treatment, days 
111 
Median time until first alcohol consumption or termination 
of treatment, days 
64 
Number (%) of patients who completed the study with no 
evidence of alcohol consumption 
6 (20.7%) 
Source: Specka et al., 2014. 
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Naltrexone/Acamprosate Study. The COMBINE study, conducted by Anton et al (2006), 
randomized 1,383 alcohol-dependent patients to one of nine treatment groups to receive 
naltrexone, acamprosate, both, and/or both placebos, with and without CBI. A ninth group 
received CBI only (see Tables 25, 26, and 27). Note that the below tables show only those results 
that were statistically significant; details on other results are included in Chapter Two. 
Table 25 
Naltrexone/Acamprosate Study: Overview 
Element Description 
Study design Randomized, controlled, multicenter 
Indication Alcohol use disorder 
Investigational drug Naltrexone, acamprosate 
Placebo/control Placebo, control 
Treatment arms Naltrexone/no CBI (n=154), acamprosate/no CBI (n=152), 
acamprosate + naltrexone/no CBI (n=148), 
placebo/no CBI (n=153), naltrexone/CBI (n=155), 
acamprosate/CBI (n=151), acamprosate + naltrexone/CBI 
(n=157), placebo/CBI (n=156), CBI only (n=157) 
Study population Recently alcohol-abstinent volunteers 
Number of subjects 1,383 
Study duration 16-week treatment period, up to one-year follow-up period 
Location(s) United States (11 clinical sites) 
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Psychosocial intervention CBI 
CBI=combined behavioral intervention. 
Source: Anton et al., 2006. 
Table 26 
Naltrexone/Acamprosate Study: Key Results (1) 
Endpoint/Outcome No CBI CBI 
Naltrexone × CBI 
Interaction 
Placebo 
(n=305) 
Naltrexone 
(n=302) 
Placebo 
(n=305) 
Naltrexone 
(n=309) 
Percent days abstinent, 
mean (SD) 
75.1 (25.46) 80.6 (25.37) 79.2 (25.32) 77.1 (25.49) 
CBI=combined behavioral intervention; SD=standard deviation. 
Source: Anton et al., 2006. 
Table 27 
Naltrexone/Acamprosate Study: Key Results (2) 
Endpoint/Outcome Control Intervention 
Naltrexone Main Effect Placebo (n=612) Naltrexone (n=614) 
Patients with ≥1 heavy drinking day 
during treatment, n (%) 
437 (71.4) 419 (68.2) 
Source: Anton et al., 2006. 
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Naltrexone/Acamprosate/Disulfiram Study. A randomized, multicenter, open-label 
study conducted by Laaksonen et al (2007) compared the efficacy of naltrexone, acamprosate, 
and disulfiram in the treatment of alcohol dependence (see Tables 28 and 29). 
Table 28 
Naltrexone/Acamprosate/Disulfiram Study: Overview 
Element Description 
Study design Randomized, open-label, multicenter, comparative 
effectiveness 
Indication Alcohol use disorder 
Investigational drug Naltrexone, acamprosate, disulfiram 
Placebo/control None 
Treatment arms Naltrexone (n=81), acamprosate (n=81), disulfiram (n=81) 
Study population Males and females aged 25 to 65 years, voluntarily seeking 
outpatient treatment for alcohol problems 
Number of subjects 243 
Study duration 119 weeks: 12-week continuously supervised medication 
period, up to 52-week targeted medication period, 
67-week follow-up period 
Location(s) Finland (3 clinical sites) 
Psychosocial intervention Brief manual-based cognitive behavioral intervention 
Source: Laaksonen et al., 2007. 
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Table 29 
Naltrexone/Acamprosate/Disulfiram Study: Key Results 
Endpoint/Outcome Naltrexone 
(n=81) 
Acamprosate 
(n=81) 
Disulfiram 
(n=81) 
Time to first heavy drinking day during 
CM period, days (mean±SD) 
22.0±22.0 17.6±22.0 46.6±27.5 
Time to first drink during CM period, 
days (mean±SD) 
16.2±20.2 11.4±17.0 30.4±27.8 
Abstinent days/week during CM period 
(mean±SD) 
4.6±2.0 4.5±2.1 6.3±0.9 
CM=continuous medication; SD=standard deviation. 
Source: Laaksonen et al., 2007. 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 83 
 Despite strong evidence that the use of these medications is effective and safe in 
individuals with substance use disorders, as with any treatment, there are certain considerations 
that should be made before implementing therapy. 
Safety Considerations 
 Although the focus of this paper is the efficacy of these pharmacological therapies in the 
treatment of substance use disorders and prevention of relapse, it is important to note and discuss 
the safety considerations that should be made both before and during use. 
Adverse events. Naltrexone use has been shown to be generally well tolerated in patients 
for the treatment of opioid use disorder. In the study conducted by Krupitsky et al (2011), 
26% of patients treated with naltrexone experienced a drug-related adverse event; 2% of those 
patients experienced a serious adverse event. Although the frequency of adverse events was 
higher among patients receiving naltrexone (50% versus 32%, respectively), the frequency of 
serious adverse events was higher among patients receiving placebo (2% versus 3%, 
respectively). The most common adverse events occurring in patients treated with naltrexone in 
this study included nasopharyngitis (7% of patients), insomnia (6%), hypertension (5%), 
influenza (5%), and injection site pain (5%). 
In the study conducted by Lee et al (2016), a similar outcome was observed: patients 
receiving naltrexone had a higher frequency of adverse events compared to patients receiving 
usual treatment (77.8% versus 58.1%, respectively), but patients receiving usual treatment had a 
higher frequency of serious adverse events compared to patients receiving naltrexone 
(29.0% versus 10.5%, respectively). These serious adverse events included depression or 
suicidality (naltrexone: 2.0%; usual treatment: 3.9%), death (naltrexone: 1.3%; usual 
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treatment: 3.2%), and any overdose (naltrexone: 0%; usual treatment: 4.5%), of which 
2.6% were nonfatal and 1.9% were fatal. 
In the study conducted by Lee et al (2018) comparing extended-release naltrexone and 
buprenorphine-naloxone, the proportion of patients experiencing adverse events was similar 
between the two treatment groups: 54% and 52%, respectively. The most common types of 
adverse events included those falling under the following categories: injection site reaction; 
gastrointestinal; psychiatric disorders; injury, poisoning, and procedural complications; 
infections and infestations; and nervous system disorders. Serious adverse events occurred in a 
similar proportion and at a similar frequency in the naltrexone and buprenorphine-naloxone 
treatment groups: 14% (39 events) and 11% (35 events), respectively. The study conducted by 
Ling et al (1996) further supports the safety of buprenorphine: no serious adverse effects were 
reported, and the authors stated that, at the clinical level, they “believe buprenorphine to be a 
safe drug” (Ling et al., 1996). 
The study conducted by Strain et al (1999) supports the safety of both moderate- and 
high-dose methadone. They found no significant differences between the two treatment groups in 
regard to self-reported adverse effects; the frequency and severity of the reported adverse effects 
were low in both treatment groups. Although the study conducted by Ling et al (1996) focused 
more on the safety of buprenorphine, it was reported that adverse events were “about equally 
represented” among the three treatment groups (methadone 30 mg, methadone 80 mg, and 
buprenorphine 8 mg). 
The meta-analysis conducted by Jarosz et al (2013) assessed the safety results of several 
clinical studies on the use of naltrexone in the treatment of alcohol use disorder. The authors 
found that the most common adverse events associated with naltrexone use included headache, 
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sleeping disorder, fatigue, anxiety, and gastrointestinal disorder, which were “usually mild and 
transient” (Jarosz et al., 2013). 
In the study conducted by Tempesta et al (2000) comparing the effectiveness of treatment 
with acamprosate versus placebo, there was no significant difference in adverse events among 
the two treatment groups. The most common adverse events among patients treated with 
acamprosate included headache (7.3%), diarrhea (3.0%), and epigastric discomfort (1.2%). The 
frequency of adverse events was reported to have decreased over the study period. In the study 
conducted by Sass et al (1996), adverse events were evenly distributed between the acamprosate 
and placebo treatment groups, with 41 events occurring in each group. Diarrhea and headache 
were the most frequently reported, with 10 acamprosate-treated patients and 11 placebo-treated 
patients reporting mild or moderate diarrhea and 7 acamprosate-treated patients and 
9 placebo-treated patients reporting mild or moderate headache. Two patients, one in each 
treatment group, committed suicide during the study. 
 In the study conducted by Specka et al (2014), a total of 31 adverse events occurring in 
20 (69%) patients receiving disulfiram were reported. Seven events were considered serious; the 
remaining events were considered possibly or probably related to disulfiram treatment. There 
were no instances of acute severe alcohol-disulfiram reactions from drinking. 
 In the study conducted by Laaksonen et al (2007) that compared disulfiram, naltrexone, 
and acamprosate in the treatment of alcohol dependence, one-third of patients reported at least 
one adverse event (29.1% of acamprosate-treated patients, 31.1% of disulfiram-treated patients, 
and 39.8% of naltrexone-treated patients), with no significant difference between treatment 
groups. The most common adverse events reported in acamprosate-treated patients included 
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diarrhea and dermatological problems; in disulfiram-treated patients, tiredness and headache; and 
in naltrexone-treated patients, nausea, headache, and tiredness. 
Nutritional deficiencies. Along with their more general side effects, the nutritional 
deficiencies associated with the use of these pharmacological therapies are an important 
consideration to be made when selecting a treatment strategy and throughout treatment. 
Naltrexone in the treatment of opioid use disorder has the potential to cause anorexia, 
weight loss, nausea, and vomiting. Methadone use may cause severe constipation, abdominal 
pain, dry mouth, appetite abnormalities, hypokalemia, hypomagnesemia, and weight gain; 
dieticians treating patients who are using methadone should consider “encouraging and outlining 
a diet with adequate fluids and fiber” in order to help combat these side effects (Salz, 2014). 
Additionally, because methadone use may cause a patient to become very ill if he or she ingests 
alcohol, abstinence from drinking should be advised. Buprenorphine also has the potential to 
influence digestion and appetite; dieticians treating patients who are using buprenorphine should 
“advise patients to slowly increase fiber and make sure meals are appetizing and aromatic” (Salz, 
2014). 
Naltrexone in the treatment of alcohol use disorder may cause similar side effects as in 
the treatment of opioid use disorder (anorexia, weight loss, nausea, and vomiting). Disulfiram 
use may cause nausea and vomiting and will cause a patient to become very ill if he or she 
ingests alcohol. The potential for this severe reaction is an important consideration for dieticians 
who may be treating patients using disulfiram, who should ensure that “all traces of alcohol are 
eliminated from patients’ diets, including any that may be used in recipes” (Salz, 2014). Lastly, 
acamprosate use may cause an increase in appetite, an increase in weight, and changes in taste. 
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Substance abuse is associated with poor nutrition in individuals. Because nutrient 
deficiencies “can lead to symptoms of depression, anxiety, and low energy,” which can in turn 
trigger a relapse in patients, it is imperative to address patients’ nutrition and hydration (Salz, 
2014). It has been shown that an improvement in diet and nutrition during treatment “can prevent 
resumption of substance abuse in many patients” (Grant, Houghton, & Sachan, 2004). In the 
treatment of substance use disorders, individualized nutrition counseling within the framework of 
a more comprehensive nutrition education program has been found to “significantly improve 
three-month sobriety success rates” (Salz, 2014; Grant et al., 2004). It is recommended that 
medical nutrition therapy and education in the treatment of substance use disorders aim to “heal 
and nourish the body damaged by alcohol or substance abuse, stabilize mood and reduce stress, 
reduce cravings for drugs and alcohol, address medical conditions that are co-occurring… [and] 
encourage self-care and a healthful lifestyle” (Salz, 2014). 
In the context of the use of pharmacological therapies in the treatment of substance use 
disorders, dieticians should be cautious when recommending supplements to patients “due to 
addicts’ quick-fix mindset and already-taxed bodies” (Salz, 2014). Additionally, a patient’s 
damaged liver may not be able to adequately process certain supplements, and any supplements 
ingested may negatively impact liver health. 
Medication-Assisted Therapy 
 One commonality across nearly all of the studies referenced in this paper is the use of a 
supplemental psychological therapy alongside the pharmacological therapy being investigated. 
Psychosocial therapy should be utilized alongside pharmacological intervention in the treatment 
of substance use disorders, as this has been shown to be the most optimal treatment strategy in 
individuals with substance use disorders. 
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A systematic review by Dugosh et al (2016) assessed current literature on the optimal 
psychosocial interventions to use alongside treatment with methadone, buprenorphine, and 
naltrexone for opioid use disorder. Twenty-seven articles were included in this review. 
Fourteen studies evaluated the effectiveness of providing various psychosocial treatments in 
combination with methadone maintenance therapy. Treatments included contingency 
management, cognitive-behavioral therapy, behavioral drug and human immunodeficiency virus 
risk reduction counseling, acceptance and commitment therapy, general supportive counseling, 
and a web-based behavioral intervention. 
Four studies assessed the efficacy of contingency management in conjunction with 
methadone maintenance therapy. One study randomized patients to receive either methadone 
maintenance therapy plus contingency management or methadone maintenance therapy alone as 
usual. Contingency management patients earned prizes for providing morphine-negative urine 
samples and attending methadone maintenance therapy. Patients randomized to methadone 
maintenance therapy alone were encouraged to stop using when they provided a 
morphine-positive urine sample. Patients treated with contingency management provided 
significantly more morphine-negative urine samples (p<0.001) and attended significantly more 
days of treatment (p<0.01) than patients treated with methadone maintenance therapy alone. 
Another similar study randomized patients to receive either methadone maintenance 
therapy plus contingency management or methadone maintenance therapy alone as usual. 
Patients receiving contingency management earned prizes for providing opioid-negative urine 
samples and attending methadone maintenance therapy. Patients receiving contingency 
management had significantly more weeks of treatment attendance, higher rates of methadone 
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maintenance therapy completion, and longer durations of continued abstinence compared to 
patients receiving methadone maintenance therapy alone. 
An important conclusion to be drawn from the aforementioned studies is that these 
pharmacological therapies are shown to be effective when used as part of a more comprehensive 
treatment program that typically includes various forms of psychosocial therapy. This strategy is 
commonly referred to as medication-assisted therapy and is discussed in detail in the next 
chapter. 
Co-Occurring Opioid and Alcohol Use 
 There is mounting evidence that opioids and alcohol are commonly used together, which 
is especially concerning because both substances “act as central nervous system depressants,” 
potentially leading to “significant respiratory depression contributing to overdose risk” 
(Witkiewitz & Vowles, 2018). 
Population-based samples in the United States have found that using nonmedical 
prescription opioids and having an opioid use disorder increases the risk of also having an 
alcohol use disorder among adults aged 18 years and older in the 2012 to 2013 National 
Epidemiologic Survey on Alcohol and Related Conditions-III sample (Witkiewitz & Vowles, 
2018). The 2015 National Survey on Drug Use and Health found that past-year alcohol users 
aged 12 years and older were “more likely to have misused prescription drugs, including pain 
relievers, in the past year” (Witkiewitz & Vowles, 2018). 
Effect of alcohol use on opioid use disorder treatment. The aforementioned open-label, 
randomized, controlled effectiveness study conducted by Lee et al (2016) that explored the 
efficacy of extended-release naltrexone in reducing opioid relapse compared with “treatment as 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 90 
usual” in opioid-dependent criminal justice system offenders offers insight into the effect of 
alcohol use on opioid use disorder treatment. A subsequent analysis of the study aimed to 
identify potential moderators of the medication’s effect. Patients’ relapse status at a six-month 
follow-up was regressed on treatment group (XR-NTX or treatment as usual), baseline 
covariates, and their two-way interaction to identify moderator effects. These baseline covariates 
included summary scores for depression; socialization; drug abuse risk; medical, psychiatric, and 
employment status; alcohol use; legal and family/social issues; demographics; history of 
substance use, physical, and other abuse; suicidal thoughts; and quality of life measures. 
 Researchers found that the only significant (p<0.05) moderator of XR-NTX was “drank 
alcohol to intoxication,” as defined by the Addiction Severity Index, in the 30 days prior to 
randomization. Those patients who reported such intoxication that were assigned to XR-NTX 
relapsed to opioids at a rate similar to treatment as usual (56% versus 58%, respectively), while 
those without such intoxication in the prior 30 days had a lower rate of opioid relapse (41% in 
the XR-NTX group versus 65% in the treatment as usual group; p<0.04). 
 Although naltrexone is indicated for the treatment of both opioid and alcohol use 
disorders, the finding that XR-NTX was less effective in preventing opioid relapse in patients 
with recent alcohol intoxication “appears to contradict this supposition” (Friedmann et al., 2018). 
The researchers note that, because an individual must be fully abstinent from opioids prior to 
XR-NTX initiation, “these heavy drinking subjects might represent individuals who have 
substituted alcohol for opioids, and their drinking might be a marker for a more severe 
polysubstance addictive disorder and less stable remission that is more prone to relapse” 
(Friedmann et al., 2018). It is also important to note that, in the treatment of alcohol use disorder, 
XR-NTX works best for patients who achieve abstinence prior to initiation, so it is possible that 
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these patients’ heavy drinking might have lowered the effectiveness of XR-NTX for opioid use 
disorder. 
Effect of opioid use on alcohol use disorder treatment. A secondary analysis of the 
aforementioned COMBINE study (Anton et al., 2006) by Witkiewitz et al (2018) aimed to 
examine associations between baseline opioid misuse with time to first drinking day, time to first 
heavy drinking day, and the frequency and intensity of drinking during treatment and at one year 
following treatment, based on latent profile analysis. Opioid misuse was defined as the use of 
illicit or prescription opioids without a prescription or not as directed in the previous six months, 
in the absence of opioid use disorder. Of the 1,226 patients in the COMBINE study who received 
medications and a behavioral intervention, 70 (5.7%) met the opioid misuse definition. Analyses 
conducted at month 4 (during treatment) and at month 16 (one year following treatment) 
included percent drinking days, drinks per drinking day, percent heavy drinking days, and 
maximum number of drinks on the peak drinking occasion. 
 Results showed that opioid misuse in these patients predicted a 38% greater chance of 
heavy drinking during treatment (p=0.001). The effect of opioid misuse on time to any drinking 
was not statistically significant (p=0.06). The average time to first heavy drinking day and time 
to first any drinking day was 125 days and 91 days, respectively, in patients without any drug 
use; and 77 days and 62 days, respectively, in patients with opioid misuse. Researchers defined 
three profiles based on average drinking rates: frequent heavy drinking, occasional heavy 
drinking, and infrequent drinking. During treatment, the odds of being in the frequent heavy 
drinking profile versus the infrequent drinking profile were 2.9 times greater in patients who 
misused opioids. At the one-year follow-up, these odds were 2.7 times greater in patients who 
misused opioids. Results also indicated that opioid misuse affected medication adherence; 
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patients who misused opioids showed significantly lower rates of adherence (81.7% mean 
percent adherent) than those with no opioid or other drug use (90.8% mean percent adherent). 
 Because patients with opioid use disorder were excluded from participation in the 
COMBINE study, researchers noted that their observed associations between opioid misuse and 
alcohol use disorder treatment outcomes “likely represent a lower bound of the impact of 
problematic opioid use on alcohol treatment outcomes” and called for future research to consider 
the differences between the use of opioids as prescribed versus misuse versus opioid use disorder 
(Witkiewitz, Votaw, Vowles, & Kranzler, 2018). Future research with targeted recruitment of 
patients with co-occurring opioid and alcohol use disorders would “provide a better test of the 
association between opioid misuse and alcohol relapse risk” and vice versa (Witkiewitz et al., 
2018). 
Potential interventions to treat co-occurring opioid and alcohol use disorders. Currently, 
there is a lack of research on therapeutic interventions in the treatment of co-occurring opioid 
and alcohol use disorders. However, the use of extended-release naltrexone as a potentially 
efficacious treatment option has been proposed. Saxon (2018) posits that treatment with 
extended-release naltrexone in patients with underlying alcohol use disorder who use opioids 
“would address poor medication adherence and also prevent any untoward effects of opioids that 
destabilize such patients.” Additionally, Saxon calls attention to the need for researchers to 
“study carefully the phenomenology of and optimal treatments for the large number of patients 
out in the real-world who have concurrent alcohol and other substance use disorders” (2018). 
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Chapter Five: Discussion 
Addiction and Relapse 
 It is commonly thought that individuals with addiction are bad people who consistently 
choose to use drugs and/or alcohol. Addiction is much more complex than simply deciding 
whether or not to use, as is the process of recovery from addiction. Recovery is typically broken 
down into three stages: abstinence (transition), repair (early recovery), and growth (ongoing 
recovery), each with its own risks of relapse and developmental tasks (Melemis, 2015). The 
typical risks of relapsing in the abstinence stage of recovery include “physical cravings, poor 
self-care, wanting to use just one more time, and struggling with whether one has an addiction” 
(Melemis, 2015). Clinical experience has shown that common causes of relapse in the repair 
stage include poor self-care and not attending self-help groups, while common causes of relapse 
in the growth stage stem from individuals wanting to put their addiction behind them, focusing 
less on self-care as their lives improve, attending fewer self-help meetings because they feel they 
are not learning anything new, and thinking they should be able to control a relapse or avoid its 
consequences (Melemis, 2015). 
 Although individuals who are addicted to drugs and/or alcohol may achieve sobriety or 
“recovery,” it does not mean that they no longer have an addiction. Additionally, individuals “do 
not achieve recovery by just not using” (Melemis, 2015). While drug/alcohol abstinence is 
necessary for recovery, abstinence alone should not be the primary goal of addiction treatment. 
Rather, the goal should be to “help individuals recognize the early warning signs of relapse and 
develop coping skills to prevent relapse early, when the chances of success are greatest” 
(Melemis, 2015). 
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 Relapse is a part of nearly every addict’s journey in recovery. Relapse to drug and/or 
alcohol use is not as straightforward as simply picking up a drink or drug. It is a gradual process 
that has previously been broken into up to 11 distinct phases but is best understood in terms of 
three stages: emotional, mental, and physical (Melemis, 2015). The process of relapsing involves 
a number of emotions, thoughts, and actions that often manifest weeks or even months prior to 
an actual physical relapse. Because relapse represents a significant challenge in addiction 
treatment, identifying potential therapeutic modalities that may aid in relapse prevention is of 
high importance. 
Pharmacological Therapies for Relapse Prevention 
 A number of pharmacological therapies have been shown to be safe and effective in the 
maintenance treatment of opioid and/or alcohol dependence, as well as the prevention of relapse. 
The efficacy of naltrexone, buprenorphine/buprenorphine-naloxone, methadone, acamprosate, 
and disulfiram in relapse prevention in patients with opioid and alcohol dependence has been 
demonstrated in a number of studies in which treatment with these medications was associated 
with decreases in opioid/alcohol craving, longer time to relapse, decreased number of drinking 
days and opioid use days, improved treatment retention, and greater rates of abstinence. 
Opioid dependence. Naltrexone was first studied as a treatment for drug dependence 
(specifically heroin addiction) in the 1970s. Early studies were plagued by subject 
noncompliance, and it wasn’t until its extended-release form was developed that compliance 
began to improve. It was approved for the treatment of alcohol use disorder in 2006 and opioid 
use disorder in 2010. 
Naltrexone in the treatment of opioid dependence has been shown to reduce opioid 
cravings, improve treatment retention, result in longer time to relapse, and improve overall 
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abstinence (Krupitsky et al., 2011; Lee et al., 2016). Buprenorphine in the treatment of opioid 
dependence has been shown to reduce the incidence of relapse and decrease cravings in 
compliant patients (Tkacz et al., 2011). Methadone in the treatment of opioid dependence has 
been shown to decrease opioid use and be effective in treatment retention. In a study directly 
comparing high-dose methadone, low-dose methadone, and buprenorphine, treatment with 
high-dose methadone was associated with improved treatment retention, decreased opioid use, 
and decreased craving (Ling et al., 1996). A study comparing naltrexone and 
buprenorphine-naloxone found that both treatments were associated with decreased craving and, 
over time, were similarly effective in decreasing the risk of relapse, but naltrexone treatment was 
more difficult to start than buprenorphine-naloxone treatment (Lee et al., 2018). 
Alcohol dependence. The use of opioid antagonists as pharmacological adjuncts in the 
treatment of alcohol dependence has been investigated since the early 1990s. Naltrexone in the 
treatment of alcohol dependence has been shown to decrease cravings, result in longer time to 
relapse and fewer drinking days, and improve abstinence (O’Malley, 1996; Jarosz et al., 2013; 
Anton et al., 1999). 
A 1994 study by Swift et al sought to assess the effects of naltrexone on ethanol 
intoxication. In their double-blind, crossover study, 20 non-alcoholic volunteers received 
naltrexone on one day and a matching placebo on another. Subjects consumed a moderate 
amount of alcohol on both days approximately one hour after receiving either naltrexone or 
placebo. It was found that the pharmacokinetic activity and cognitive performance impairment of 
alcohol was similar for both naltrexone and placebo treatments. However, subjects reported 
“lower levels of stimulation and higher levels of sedation from alcohol” on the day they received 
naltrexone compared to the day they received placebo (O’Malley, 1996). Additionally, 75% of 
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subjects reported liking alcohol more after receiving placebo than after receiving naltrexone, 
indicating that naltrexone may reduce alcohol consumption by “decreasing the positive 
reinforcing effects of alcohol and selectively intensifying some of the discriminative features of 
alcohol intoxication, such as sedation” (O’Malley, 1996). 
Acamprosate in the treatment of alcohol dependence has been shown to result in longer 
time to relapse and improve rates of relapse, with decreased frequency and quantity of alcohol 
consumption (Tempesta et al., 2000; Sass et al., 1996). Disulfiram in the treatment of alcohol 
dependence is associated with improved rates of abstinence and treatment compliance, as well as 
fewer drinking days (Specka et al., 2014; Jørgensen et al., 2011). A study comparing treatment 
with naltrexone, acamprosate, and disulfiram found statistically significant differences in time to 
first heavy drinking day, time to first drinking day, and number of abstinent days per week in 
favor of disulfiram; these differences were no longer statistically significant over the 
second phase of the study. Patients treated with disulfiram experienced significantly more 
abstinent days than those treated with naltrexone and acamprosate. The severity of alcohol 
dependence was significantly reduced in all three treatment groups, and quality of life was 
significantly improved in all three treatment groups (Laaksonen et al., 2007). 
There is ample evidence to suggest that the use of pharmacological therapies, specifically 
naltrexone, buprenorphine/buprenorphine-naloxone, methadone, acamprosate, and disulfiram, is 
safe and effective in the maintenance treatment of opioid and alcohol dependence, as well as the 
prevention of relapse. The results of the aforementioned studies indicate that treatment with these 
medications is associated with improved outcomes in patients. While the use of these 
medications may be beneficial, there is no foolproof method of preventing opioid and/or alcohol 
relapse – pharmacological or otherwise. 
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An important aspect that many of the aforementioned studies share is a treatment 
duration of between three and six months. The first 90 days of addiction recovery are widely 
considered the most important, and it has been shown that individuals with substance use 
disorders “need at least three months in treatment to significantly reduce or stop their drug use” 
(National Institute on Drug Abuse, 2018b). While long-term treatment with various therapies are 
necessary for lasting abstinence and recovery, the use of pharmacological therapies during the 
first three to six months of treatment “can be very useful in stabilizing those in early recovery 
and helping them to manage the symptoms of withdrawal during detox” (American Addiction 
Centers, 2019). 
Medication-Assisted Therapy for Addiction 
 Medication-assisted therapy is “the use of medications in combination with counseling 
and behavioral therapies” (FDA, 2019). The studies referenced in this paper support not only the 
efficacy of certain pharmacological therapies in opioid and alcohol dependence and relapse 
prevention but highlight the importance of supplementing this type of therapy with other forms 
of non-pharmacological therapies, including cognitive behavioral therapy, general counseling, 
and other types of support (12-step programs, etc.). 
 Medications have been used in the treatment of addiction since the late eighteenth 
century. Because so many later proved harmful and ineffective, in the mid- to late-twentieth 
century, “a deep suspicion of medications became ingrained into the very DNA of 
U.S. communities of recovery and many branches of addiction treatment” (White, 2014). 
Although significant progress has been made since, a certain level of suspicion of 
medication-assisted therapy for addiction has persisted over the years. 
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 Medication-assisted therapy has been shown to improve treatment outcomes in patients 
with substance use disorders and result in reductions in mortality rates and criminal activity 
(Rieckmann, Kovas, & Rutkowski, 2010). Despite this, FDA-approved medications for the 
treatment of opioid use disorder remain “markedly underutilized” (Volkow et al., 2014). When 
prescribed and monitored properly, medication-assisted therapies have been proven to be not 
only effective in helping patients recover but also safe, cost-effective, and effective in reducing 
the risk of overdose (Volkow et al., 2014). In an article published in The New England Journal of 
Medicine, Volkow et al attributes the low access to and utilization of medication-assisted 
therapies to “a paucity of trained prescribers and negative attitudes and misunderstandings about 
addiction medications held by the public, providers, and patients” (2014). 
In a longitudinal study conducted by Rieckmann et al (2010), single state authority 
directors and/or representatives across the country were interviewed in order to collect data on 
the perceptions of the adoption of medication-assisted therapy in substance abuse treatment. 
While access to medication was considered a priority, a slight lag in implementation was 
reported. Of the medications offered across treatment programs, methadone had the highest mean 
implementation, followed by buprenorphine, naltrexone, and disulfiram. It was found that “the 
prevailing public attitude that drug addiction should not be treated (or substituted) with another 
‘drug’ was a common and significant barrier” to the utilization of medication-assisted therapy 
(Rieckmann et al., 2010). A lack of funding to cover the costs of medications, as well as a lack of 
support from policy makers and legislators, also presented major barriers. 
 Expanding access to medication-assisted therapy for individuals with substance use 
disorders is “a crucial component of the effort to help patients recover” (Volkow et al., 2014). If 
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the current addiction epidemic is to be tackled to any significant degree, prioritizing the growth 
of this type of treatment is necessary. 
Proposed Further Study 
 In designing a future study on this topic, the author of this paper would investigate the 
efficacy of medication-assisted therapy (pharmacological therapy plus psychosocial therapy) 
compared to pharmacological therapy alone and psychosocial therapy alone in patients with 
opioid and alcohol dependence. While the pharmacological agent being used would be of 
interest, of greater interest would be the effectiveness of psychosocial therapy in conjunction 
with the pharmacological treatment. 
 The duration of the study would be one year, including a six-month treatment period and 
a six-month follow-up period. Male and female patients aged 18 to 65 years with diagnosed 
opioid and/or alcohol dependence and without any comorbid diagnosed psychiatric disorders 
would be screened for inclusion in the study. Approximately 300 patients would be stratified by 
type of primary substance use disorder: opioid or alcohol. Both sets of patients would then be 
randomized to one of three treatment groups: medication-assisted therapy, pharmacological 
therapy, or psychosocial therapy. Patients with opioid use disorder randomized to the 
medication-assisted therapy or pharmacological therapy group would receive either naltrexone, 
buprenorphine, or methadone. Patients with alcohol use disorder randomized to the 
medication-assisted therapy or pharmacological therapy group would receive either naltrexone, 
acamprosate, or disulfiram. This would allow for additional analyses comparing the efficacy of 
the various pharmacological agents. 
 Additionally, patients randomized to the medication-assisted therapy or psychosocial 
therapy group would receive either individual cognitive-behavioral therapy, contingency 
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management therapy, group counseling, or 12-step facilitation therapy. This would allow for 
additional analyses comparing the efficacy of and compliance with various psychosocial 
interventions. Patients randomized to these groups would receive their respective type of therapy 
three times per week; all enrolled patients would be required to meet with a study physician once 
per week. 
 Similar to previous studies, efficacy outcomes would include time to first relapse, 
cumulative abstinence duration, number of substance use days, substance craving, and treatment 
retention. Abstinence would be confirmed via urine testing; craving would be assessed using a 
self-report visual analog scale of the perceived need for opioids/alcohol. The author would also 
be interested in assessing patients’ level of personal satisfaction with their pharmacological 
and/or psychosocial treatments, in order to better understand which formats would promote 
patient compliance and likely lead to more successful long-term treatment outcomes. 
Conclusions 
 Addiction to drugs and/or alcohol is one of the most prevalent yet commonly 
misunderstood public health issues worldwide. While it may be simpler and at times more 
convenient to blame an individual’s addiction on what can be viewed as an inherently immoral 
nature, that is simply not the case. The chronic abuse of a substance (or number of substances) 
that characterizes addiction has serious effects on the brain, including those areas associated with 
judgment, decision making, learning, memory, and behavior control (American Psychiatric 
Association, 2017). 
In addition to the profound consequences of addiction on affected individuals, their loved 
ones, and their personal lives, the prevalence of substance use disorders also presents a 
significant societal and economic burden. Yearly in the United States, addiction to drugs and 
IDENTIFYING THE OPTIMAL THERAPEUTIC STRATEGY 101 
alcohol results in the deaths of tens of thousands of individuals; and the use and abuse of drugs, 
alcohol, and nicotine costs over $700 billion related to health care, crime, and lost productivity 
(National Institute on Drug Abuse, 2018a). 
 The concept of addiction has existed for hundreds of years, and treatment options have 
evolved over time. Today, treatments for substance use disorders vary widely and include many 
different forms of behavioral therapy (cognitive-behavioral therapy, contingency management 
interventions, motivational enhancement therapy, family behavior therapy, 12-step facilitation 
therapy), which may be carried out in both individual and group settings; pharmacological 
therapy alone; and medication-assisted therapy involving various pharmacological agents along 
with supplemental counseling and behavioral therapy. 
 The aim of this paper was to determine the efficacy of current FDA-approved 
pharmacological therapies in the prevention of relapse in patients with opioid use disorder and 
alcohol use disorder. The efficacy of naltrexone, buprenorphine/buprenorphine-naloxone, 
methadone, acamprosate, and disulfiram in relapse prevention in patients with opioid and alcohol 
dependence has been demonstrated in a number of studies in which treatment with these 
medications was associated with decreases in opioid/alcohol craving, longer time to relapse, 
decreased number of drinking days and opioid use days, improved treatment retention, and 
greater rates of abstinence. 
 While the current evidence supports the use of these pharmacological therapies in 
substance use disorder treatment, the general consensus among professionals in the field is that 
pharmacological therapy along with counseling and behavioral therapy, known as 
medication-assisted therapy, provides the best treatment outcomes for patients. Despite this 
knowledge, access to medication-assisted therapies in substance use disorder treatment is limited 
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and commonly misunderstood, both by the public and by professionals. Various barriers to 
access, including misconceptions about treatment and a lack of qualified health care 
professionals, are a significant problem, as our country’s current opioid epidemic cannot be 
resolved without providing adequate treatment for those with underlying substance use disorders. 
 The increased morbidity associated with opioid and alcohol co-use, as well as the adverse 
effects of opioid use on alcohol use disorder treatment outcomes and alcohol use on opioid use 
disorder treatment outcomes, present another significant challenge in successfully treating 
addiction. Additional research on the association between opioid and alcohol use and potential 
therapeutic interventions for the treatment of co-occurring disorders is needed. 
Although our understanding of addiction has progressed significantly over the years, the 
current state of our country in regard to the prevalence of substance abuse speaks to the 
continued need to educate the public and health care professionals about substance use disorders 
and significantly expand access to treatment options, especially medication-assisted therapies. 
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